THE FOUNDATION FOR AIDS RESEARCH: Form 990, tax year 2011

View the entire original 990 at ProPublica ↗

Organization: THE FOUNDATION FOR AIDS RESEARCH (EIN 13-3163817)
Tax period: 2011-10-01 to 2012-09-30
Filed: 2013-06-26
IRS object ID: 201321779349300822
Schema version: 2011v1.5
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Timestamp	2013-06-26T13:24:51-05:00	Timestamp
Tax Period End Date	2012-09-30	TaxPeriodEndDate

Preparer Firm PreparerFirm

Preparer Firm Business Name PreparerFirmBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	GRANT THORNTON LLP	BusinessNameLine1

Preparer Firm US Address PreparerFirmUSAddress

Field	Value	IRS element (for citing)
Address Line1	666 THIRD AVENUE	AddressLine1
City	NEW YORK	City
State	NY	State
ZIP Code	100174057	ZIPCode

Field	Value	IRS element (for citing)
Return Type	990	ReturnType
Tax Period Begin Date	2011-10-01	TaxPeriodBeginDate

Filer Filer

Field	Value	IRS element (for citing)
EIN	133163817	EIN

Name Name

Field	Value	IRS element (for citing)
Business Name Line1	THE FOUNDATION FOR AIDS RESEARCH	BusinessNameLine1

Field	Value	IRS element (for citing)
In Care Of Name	% BRADLEY JENSEN	InCareOfName
Name Control	FOUN	NameControl
Phone	2128061600	Phone

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	120 wall street 13TH FLOOR	AddressLine1
City	NEW YORK	City
State	NY	State
ZIP Code	100053908	ZIPCode

Officer Officer

Field	Value	IRS element (for citing)
Name	Brad Jensen	Name
Title	Asst Treasurer	Title
Date Signed	2013-06-26	DateSigned
Authorize Third Party	true	AuthorizeThirdParty

Preparer Preparer

Field	Value	IRS element (for citing)
Name	Scott Thompsett	Name
Phone	2125990100	Phone

Field	Value	IRS element (for citing)
Tax Year	2011	TaxYear
Build TS	2016-02-24 21:20:13Z	BuildTS

Form 990 IRS990

Doing Business As DoingBusinessAs

Field	Value	IRS element (for citing)
Business Name Line1	AMFAR	BusinessNameLine1

Field	Value	IRS element (for citing)
Name Of Principal Officer Person	KEVIN FROST	NameOfPrincipalOfficerPerson

Address Principal Officer US AddressPrincipalOfficerUS

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1
City	new york	City
State	NY	State
ZIP Code	10005	ZIPCode

Field	Value	IRS element (for citing)
Gross Receipts	44785693	GrossReceipts
Group Return For Affiliates	false	GroupReturnForAffiliates
Organization501c3	X	Organization501c3
Web Site	WWW.AMFAR.ORG	WebSite
Type Of Organization Corporation	X	TypeOfOrganizationCorporation
Year Formation	1983	YearFormation
State Legal Domicile	NY	StateLegalDomicile
Activity Or Mission Description	amfar is dedicated to ending the global aids epidemic through innovative research.	ActivityOrMissionDescription
Nbr Voting Members Governing Body	20	NbrVotingMembersGoverningBody
Nbr Independent Voting Members	20	NbrIndependentVotingMembers
Total Nbr Employees	90	TotalNbrEmployees
Total Nbr Volunteers	138	TotalNbrVolunteers
Total Gross UBI	0	TotalGrossUBI
Contributions Grants Prior Year	31689016	ContributionsGrantsPriorYear
Contributions Grants Current Year	33247849	ContributionsGrantsCurrentYear
Program Service Revenue Prior Year	0	ProgramServiceRevenuePriorYear
Program Service Revenue CY	0	ProgramServiceRevenueCY
Investment Income Prior Year	885610	InvestmentIncomePriorYear
Investment Income Current Year	1178972	InvestmentIncomeCurrentYear
Other Revenue Prior Year	-5259666	OtherRevenuePriorYear
Other Revenue Current Year	-7234513	OtherRevenueCurrentYear
Total Revenue Prior Year	27314960	TotalRevenuePriorYear
Total Revenue Current Year	27192308	TotalRevenueCurrentYear
Grants And Similar Amnts Prior Year	6694401	GrantsAndSimilarAmntsPriorYear
Grants And Similar Amnts CY	8086344	GrantsAndSimilarAmntsCY
Benefits Paid To Members Prior Year	0	BenefitsPaidToMembersPriorYear
Benefits Paid To Members CY	0	BenefitsPaidToMembersCY
Salaries Etc Prior Year	8447012	SalariesEtcPriorYear
Salaries Etc Current Year	8864151	SalariesEtcCurrentYear
Total Prof Fundrsng Exp Prior Year	403813	TotalProfFundrsngExpPriorYear
Total Prof Fundrsng Exp CY	491117	TotalProfFundrsngExpCY
Total Fundrsng Exp Current Year	4654226	TotalFundrsngExpCurrentYear
Other Expense Prior Year	10565187	OtherExpensePriorYear
Other Expenses Current Year	11261191	OtherExpensesCurrentYear
Total Expenses Prior Year	26110413	TotalExpensesPriorYear
Total Expenses Current Year	28702803	TotalExpensesCurrentYear
Revenues Less Expenses Prior Year	1204547	RevenuesLessExpensesPriorYear
Revenues Less Expenses CY	-1510495	RevenuesLessExpensesCY
Total Assets BOY	38004314	TotalAssetsBOY
Total Assets EOY	40388195	TotalAssetsEOY
Total Liabilities BOY	6564229	TotalLiabilitiesBOY
Total Liabilities EOY	9636091	TotalLiabilitiesEOY
Net Assets Or Fund Balances BOY	31440085	NetAssetsOrFundBalancesBOY
Net Assets Or Fund Balances EOY	30752104	NetAssetsOrFundBalancesEOY
Info In Schedule O Part III	X	InfoInScheduleOPartIII
Mission Description	THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMF'S LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: - AMERICAN FOUNDATION FOR AIDS RESEARCH - AMFAR - AIDS RESEARC	MissionDescription
Significant New Program Services	false	SignificantNewProgramServices
Significant Change	false	SignificantChange
Expense	8657868	Expense
Grants	3980016	Grants
Revenue	0	Revenue
Description	RESEARCH: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health. For further details, see Schedule o.	Description

Activity2 Activity2

Field	Value	IRS element (for citing)
Expense	5740184	Expense
Grants	2721868	Grants
Revenue	0	Revenue
Description	TREAT ASIA: amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) involves a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 22 adult and 21 pediatric sites throughout the region, which collaborate on a variety of projects. For further details, see Schedule o.	Description

Activity3 Activity3

Field	Value	IRS element (for citing)
Expense	3138663	Expense
Grants	0	Grants
Revenue	0	Revenue
Description	EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to stimulate broad awareness of the need for better treatment and prevention methods. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policy makers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. For further details, see Schedule O.	Description

Activity Other ActivityOther (2 entries)

ExpenseExpense	GrantsGrants	RevenueRevenue	DescriptionDescription
1974629	835851	0	MSM Initiative
2316596	548609	0	public policy

Field	Value	IRS element (for citing)
Total Of Other Program Service Exp	4291225	TotalOfOtherProgramServiceExp
Total Of Other Program Service Grnt	1384460	TotalOfOtherProgramServiceGrnt
Total Of Other Program Service Rev	0	TotalOfOtherProgramServiceRev
Total Program Service Expense	21827940	TotalProgramServiceExpense
Described In501 C3	true	DescribedIn501C3
Schedule B Required	true	ScheduleBRequired
Political Activities	false	PoliticalActivities
Lobbying Activities	true	LobbyingActivities
Subject To Proxy Tax	false	SubjectToProxyTax
Donor Advised Funds	false	DonorAdvisedFunds
Conservation Easements	false	ConservationEasements
Collections Of Art	true	CollectionsOfArt
Credit Counseling	false	CreditCounseling
Term Or Permanent Endowments	true	TermOrPermanentEndowments
Report Land Bldg Equip	true	ReportLandBldgEquip
Report Invest Oth Securities	false	ReportInvestOthSecurities
Report Prog Rel Invest	false	ReportProgRelInvest
Report Other Assets	false	ReportOtherAssets
Report Other Liabilities	true	ReportOtherLiabilities
Report Fin48 Footnote	true	ReportFin48Footnote
Independent Audit Financial Stmt	true	IndependentAuditFinancialStmt
Consolidated Audit Financial Stmt	false	ConsolidatedAuditFinancialStmt
School	false	School
Foreign Office	true	ForeignOffice
Foreign Activities	true	ForeignActivities
More Than5000 K To Organizations	true	MoreThan5000KToOrganizations
More Than5000 K To Individuals	false	MoreThan5000KToIndividuals
Professional Fundraising	true	ProfessionalFundraising
Fundraising Activities	true	FundraisingActivities
Gaming	false	Gaming
Hospital	false	Hospital
Grants To Organizations	true	GrantsToOrganizations
Grants To Individuals	false	GrantsToIndividuals
Schedule J Required	true	ScheduleJRequired
Tax Exempt Bonds	false	TaxExemptBonds
Excess Benefit Transaction	false	ExcessBenefitTransaction
Prior Excess Benefit Transaction	false	PriorExcessBenefitTransaction
Loan To Officer Or DQP	false	LoanToOfficerOrDQP
Grant To Related Person	false	GrantToRelatedPerson
Bsnss Rltnshp With Organization	false	BsnssRltnshpWithOrganization
Bsnss Rltnshp Thru Family Member	false	BsnssRltnshpThruFamilyMember
Officer Entity With Bsnss Rltnshp	false	OfficerEntityWithBsnssRltnshp
Deductible Non Cash Contributions	true	DeductibleNonCashContributions
Deductible Contributions Of Art	false	DeductibleContributionsOfArt
Terminated	false	Terminated
Partial Liquidation	false	PartialLiquidation
Disregarded Entity	false	DisregardedEntity
Related Entity	false	RelatedEntity
Related Org Controlled Entity	false	RelatedOrgControlledEntity
Transaction Related Entity	false	TransactionRelatedEntity
Transfers To Exempt Non Chrtbl Org	false	TransfersToExemptNonChrtblOrg
Activities Conducted Partnership	false	ActivitiesConductedPartnership
Schedule O Required	true	ScheduleORequired
Number Forms Transmitted With1096	98	NumberFormsTransmittedWith1096
Number W2 G Included	0	NumberW2GIncluded
Compliance With Backup Witholding	true	ComplianceWithBackupWitholding
Number Of Employees	90	NumberOfEmployees
Employment Tax Returns Filed	true	EmploymentTaxReturnsFiled
Unrelated Business Income	false	UnrelatedBusinessIncome
Foreign Financial Account	true	ForeignFinancialAccount
Name Of Foreign Country	TH	NameOfForeignCountry
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTrans
Taxable Party Notification	false	TaxablePartyNotification
Non Deductible Contributions	false	NonDeductibleContributions
Quid Pro Quo Contributions	true	QuidProQuoContributions
Quid Pro Quo Disclosure	true	QuidProQuoDisclosure
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOf
Funds To Pay Premiums	false	FundsToPayPremiums
Premiums Paid	false	PremiumsPaid
Indoor Tanning Services	false	IndoorTanningServices
Info In Schedule O Part VI	X	InfoInScheduleOPartVI
Nbr Voting Governing Body Members	20	NbrVotingGoverningBodyMembers
Number Independent Voting Members	20	NumberIndependentVotingMembers
Family Or Business Relationship	false	FamilyOrBusinessRelationship
Delegation Of Management Duties	false	DelegationOfManagementDuties
Changes To Organizing Docs	false	ChangesToOrganizingDocs
Material Diversion Or Misuse	false	MaterialDiversionOrMisuse
Members Or Stockholders	false	MembersOrStockholders
Election Of Board Members	false	ElectionOfBoardMembers
Decisions Subject To Approval	false	DecisionsSubjectToApproval
Minutes Of Governing Body	true	MinutesOfGoverningBody
Minutes Of Committees	true	MinutesOfCommittees
Officer Mailing Address	false	OfficerMailingAddress
Local Chapters	false	LocalChapters
Form990 Provided To Governing Body	true	Form990ProvidedToGoverningBody
Conflict Of Interest Policy	true	ConflictOfInterestPolicy
Annual Disclosure Covered Persons	true	AnnualDisclosureCoveredPersons
Regular Monitoring Enforcement	true	RegularMonitoringEnforcement
Whistleblower Policy	true	WhistleblowerPolicy
Document Retention Policy	true	DocumentRetentionPolicy
Compensation Process CEO	true	CompensationProcessCEO
Compensation Process Other	true	CompensationProcessOther
Investment In Joint Venture	false	InvestmentInJointVenture
States Where Copy Of Return Is Filed	AL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AK	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AZ	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AR	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CT	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	FL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	GA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	HI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	IL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	KS	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	KY	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	ME	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MD	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MN	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MS	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NH	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NJ	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NM	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NY	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NC	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OK	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OR	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	PA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	RI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	SC	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	TN	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	UT	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	VA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WV	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WI	StatesWhereCopyOfReturnIsFiled
Own Website	X	OwnWebsite
Upon Request	X	UponRequest

The Books Are In Care Of TheBooksAreInCareOf

Field	Value	IRS element (for citing)
Name Person	BRADLEY JENSEN	NamePerson
Telephone Number	2128061703	TelephoneNumber

Address US AddressUS

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1
City	new york	City
State	NY	State
ZIP Code	100053908	ZIPCode

Form990 Part VII Section A Form990PartVIISectionA (40 entries)

TitleTitle	Average Hours Per WeekAverageHoursPerWeek	Individual Trustee Or DirectorIndividualTrusteeOrDirector	OfficerOfficer	Reportable Comp From OrganizationReportableCompFromOrganization	Other CompensationOtherCompensation	Key EmployeeKeyEmployee	Highest Compensated EmployeeHighestCompensatedEmployee	Reportable Comp From Related OrgsReportableCompFromRelatedOrgs
Mathilde Krim PhD
Founding Chairman	1.0	X	X
Kenneth Cole
Chairman of the Board	1.0	X	X
Patricia J Matson
Vice Chairman	1.0	X	X
John C Simons
Vice Chairman	1.0	X	X
Wallace Sheft CPA
Treasurer	1.0	X	X
Mervyn F Silverman MDMPH
Secretary	1.0	X	X
Arlen H Andelson
Trustee	1.0	X
Harry Belafonte
Trustee (NON-voting)	1.0	X
David Bohnett
Trustee	1.0	X
Zev Braun
Trustee (non-voting)	1.0	X
Jonathan S Canno
Trustee	1.0	X
Donald Capoccia
Trustee	1.0	X
R Martin Chavez PhD
Trustee	1.0	X
Jane B Eisner
Trustee (NON-voting)	1.0	X
T Ryan Greenawalt
Trustee	1.0	X
Regan Hofmann
Trustee	1.0	X
Michael J Klingensmith
Trustee	1.0	X
Michele V McNeill PharmD
Trustee (NON-Voting)	1.0	X
Raymond F Schinazi PhD
Trustee	1.0	X
Edward Milstein
Trustee	1.0	X
Cindy Rachofsky
Trustee	1.0	X
Vincent A Roberti
Trustee	1.0	X
Bill Roedy
Trustee	1.0	X
Alan D Schwartz
Trustee (NON-VOTING)	1.0	X
Diana L Taylor
Trustee	1.0	X
Kevin Wendle
Trustee (NON-VOTING)	1.0	X
Kevin Frost
Chief Executive Officer	40.0		X	361481	54157
Bradley Jensen
ASST Treasurer, CFO	40.0		X	219053	44734
John F Logan JD PhD
ASST Secretary, VP & GC	40.0		X	200521	23268
Rowena Johnston
ASST Secretary, VP OF RESEARCH	40.0		X	155658	20326
Edward Donnelly
ASST Treasurer, ControlleR	40.0		X	137426	18055
Gregory L Boroff
Vice President of Development	40.0			223561	25028	X
Christopher Collins
Vice President, Public Policy	40.0			184540	30412	X
Annette Sohn
Vice President, TREAT Asia	40.0			193480	17365	X
AnnMarie Shannahan
Vice President, Public Info	40.0			187799	22555	X
Eric Muscatell
Director, Philanthropy	40.0			151952	20204		X
Andrew McInnes
Director, Publications	40.0			137632	38341		X
Anthony Ancona
Vice President, Human Resource	40.0			148185	11049		X
Michael Cowing
Senior Advisor for Programs	40.0			107043	16902		X	0
susan doster
chief technology officer	40.0			119668	18191		X	0

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	2527999	TotalReportableCompFromOrg
Total Reportable Comp Frm Rltd Orgs	0	TotalReportableCompFrmRltdOrgs
Total Other Compensation	360587	TotalOtherCompensation
Number Individuals GT100 K	16	NumberIndividualsGT100K
Formers Listed	false	FormersListed
Total Comp GT150 K	true	TotalCompGT150K
Compensation From Other Sources	false	CompensationFromOtherSources

Contractor Compensation ContractorCompensation (5 entries)

Address Line1AddressOfContractor/AddressUS/AddressLine1	CityAddressOfContractor/AddressUS/City	StateAddressOfContractor/AddressUS/State	ZIP CodeAddressOfContractor/AddressUS/ZIPCode	Description Of ServicesDescriptionOfServices	CompensationCompensation
aab production
64 allen street 5th floor	NEW YORK	NY	10002	events production	237400
JOSH WOODS PRODUCTION
39 WEST 14THS STREET SUITE 504	NEW YORK	NY	10011	EVENTS PRODUCTION	180000
GRANT THORNTON LLP
1901 W MEYERS ROAD SUITE 455	OAKBROOK TERRACE	IL	60181	ACCOUNTING & AUDIT	177101
THE MORRIS KING COMPANY LLC
101 FIFTH AVENUE 8TH FLOOR	NEW YORK	NY	10003	PUBLIC RELATIONS	132000
john mini consulting inc
707 savannah road	LEWES	DE	19958	direct mail	124550

Field	Value	IRS element (for citing)
Number Of Contractors GT100 K	6	NumberOfContractorsGT100K
Federated Campaigns	323724	FederatedCampaigns
Fundraising Events	18955276	FundraisingEvents
Government Grants	5008478	GovernmentGrants
All Other Contributions	8960371	AllOtherContributions
Noncash Contributions	216180	NoncashContributions
Total Contributions	33247849	TotalContributions
Total Program Service Revenue	0	TotalProgramServiceRevenue

Investment Income InvestmentIncome

Field	Value	IRS element (for citing)
Total Revenue Column	773961	TotalRevenueColumn
Exclusion	$773,961	ExclusionAmount

Income From Invest Bond Proceeds IncomeFromInvestBondProceeds

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Royalties Revenue RoyaltiesRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	124013	TotalRevenueColumn
Exclusion	$124,013	ExclusionAmount

Gross Amount Sales Assets GrossAmountSalesAssets

Field	Value	IRS element (for citing)
Securities	9014904	Securities

Less Cost Oth Basis Sales Expenses LessCostOthBasisSalesExpenses

Field	Value	IRS element (for citing)
Securities	8609893	Securities

Gain Or Loss GainOrLoss

Field	Value	IRS element (for citing)
Securities	405011	Securities

Net Gain Or Loss Investments NetGainOrLossInvestments

Field	Value	IRS element (for citing)
Total Revenue Column	405011	TotalRevenueColumn
Exclusion	$405,011	ExclusionAmount

Field	Value	IRS element (for citing)
Gross Income Fundraising Events	1389430	GrossIncomeFundraisingEvents
Cntrbtns Rprtd Fundraising Events	18955276	CntrbtnsRprtdFundraisingEvents
Fundraising Direct Expenses	8981287	FundraisingDirectExpenses

Net Income From Fundraising Events NetIncomeFromFundraisingEvents

Field	Value	IRS element (for citing)
Total Revenue Column	-7591857	TotalRevenueColumn
Exclusion	-$7,591,857	ExclusionAmount

Net Income From Gaming NetIncomeFromGaming

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	215910	GrossSalesOfInventory
Cost Of Goods Sold	2205	CostOfGoodsSold

Net Income Or Loss NetIncomeOrLoss

Field	Value	IRS element (for citing)
Total Revenue Column	213705	TotalRevenueColumn
Exclusion	$213,705	ExclusionAmount

Other Revenue Misc OtherRevenueMisc (2 entries)

DescriptionDescription	Business CodeBusinessCode	Total Revenue ColumnTotalRevenueColumn	ExclusionExclusionAmount
LIST RENTALS	900099	17365	$17,365
MISCELLANEOUS INCOME	900099	2261	$2,261

Field	Value	IRS element (for citing)
Total Other Revenue	19626	TotalOtherRevenue

Total Revenue TotalRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	27192308	TotalRevenueColumn
Exclusion	-$6,055,541	ExclusionAmount

Grants To Domestic Orgs GrantsToDomesticOrgs

Field	Value	IRS element (for citing)
Total	3180410	Total
Program Services	3180410	ProgramServices

Grants To Domestic Individuals GrantsToDomesticIndividuals

Field	Value	IRS element (for citing)
Total	0	Total

Foreign Grants ForeignGrants

Field	Value	IRS element (for citing)
Total	4905934	Total
Program Services	4905934	ProgramServices

Benefits To Members BenefitsToMembers

Field	Value	IRS element (for citing)
Total	0	Total

Comp Current Officers Directors CompCurrentOfficersDirectors

Field	Value	IRS element (for citing)
Total	2213343	Total
Program Services	1418763	ProgramServices
Management And General	447231	ManagementAndGeneral
Fundraising	347349	Fundraising

Comp Disqual Persons CompDisqualPersons

Field	Value	IRS element (for citing)
Total	0	Total

Other Salaries And Wages OtherSalariesAndWages

Field	Value	IRS element (for citing)
Total	4663290	Total
Program Services	3141792	ProgramServices
Management And General	329817	ManagementAndGeneral
Fundraising	1191681	Fundraising

Pension Plan Contributions PensionPlanContributions

Field	Value	IRS element (for citing)
Total	429229	Total
Program Services	284355	ProgramServices
Management And General	57480	ManagementAndGeneral
Fundraising	87394	Fundraising

Other Employee Benefits OtherEmployeeBenefits

Field	Value	IRS element (for citing)
Total	1091789	Total
Program Services	680056	ProgramServices
Management And General	149045	ManagementAndGeneral
Fundraising	262688	Fundraising

Payroll Taxes PayrollTaxes

Field	Value	IRS element (for citing)
Total	466500	Total
Program Services	294356	ProgramServices
Management And General	56227	ManagementAndGeneral
Fundraising	115917	Fundraising

Fees For Services Management FeesForServicesManagement

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Legal FeesForServicesLegal

Field	Value	IRS element (for citing)
Total	129221	Total
Program Services	117986	ProgramServices
Management And General	4907	ManagementAndGeneral
Fundraising	6328	Fundraising

Fees For Services Accounting FeesForServicesAccounting

Field	Value	IRS element (for citing)
Total	180472	Total
Management And General	180472	ManagementAndGeneral

Fees For Services Lobbying FeesForServicesLobbying

Field	Value	IRS element (for citing)
Total	69975	Total
Program Services	69975	ProgramServices

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	491117	Total
Fundraising	491117	Fundraising

Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees

Field	Value	IRS element (for citing)
Total	145306	Total
Management And General	145306	ManagementAndGeneral

Fees For Services Other FeesForServicesOther

Field	Value	IRS element (for citing)
Total	1203393	Total
Program Services	806166	ProgramServices
Management And General	108087	ManagementAndGeneral
Fundraising	289140	Fundraising

Advertising Advertising

Field	Value	IRS element (for citing)
Total	365252	Total
Program Services	353621	ProgramServices
Management And General	947	ManagementAndGeneral
Fundraising	10684	Fundraising

Office Expenses OfficeExpenses

Field	Value	IRS element (for citing)
Total	93190	Total
Program Services	61089	ProgramServices
Management And General	10214	ManagementAndGeneral
Fundraising	21887	Fundraising

Information Technology InformationTechnology

Field	Value	IRS element (for citing)
Total	193788	Total
Program Services	143718	ProgramServices
Management And General	32584	ManagementAndGeneral
Fundraising	17486	Fundraising

Royalties Royalties

Field	Value	IRS element (for citing)
Total	0	Total

Occupancy Occupancy

Field	Value	IRS element (for citing)
Total	1152154	Total
Program Services	791254	ProgramServices
Management And General	163489	ManagementAndGeneral
Fundraising	197411	Fundraising

Travel Travel

Field	Value	IRS element (for citing)
Total	873089	Total
Program Services	530817	ProgramServices
Management And General	1877	ManagementAndGeneral
Fundraising	340395	Fundraising

Travel Entrtnmnt Public Officials TravelEntrtnmntPublicOfficials

Field	Value	IRS element (for citing)
Total	0	Total

Conferences Meetings ConferencesMeetings

Field	Value	IRS element (for citing)
Total	959001	Total
Program Services	824293	ProgramServices
Management And General	13916	ManagementAndGeneral
Fundraising	120792	Fundraising

Interest Interest

Field	Value	IRS element (for citing)
Total	6	Total
Management And General	6	ManagementAndGeneral

Payments To Affiliates PaymentsToAffiliates

Field	Value	IRS element (for citing)
Total	0	Total

Depreciation Depletion DepreciationDepletion

Field	Value	IRS element (for citing)
Total	301791	Total
Program Services	207474	ProgramServices
Management And General	42868	ManagementAndGeneral
Fundraising	51449	Fundraising

Insurance Insurance

Field	Value	IRS element (for citing)
Total	173070	Total
Program Services	118981	ProgramServices
Management And General	24584	ManagementAndGeneral
Fundraising	29505	Fundraising

Other Expenses OtherExpenses (4 entries)

DescriptionDescription	TotalTotal	Program ServicesProgramServices	Management And GeneralManagementAndGeneral	FundraisingFundraising
PROGRAM MATERIALS	2053701	2053701
POSTAGE & SHIPPING	733949	311076	5946	416927
PROGRAM TECHNICAL SUPPORT	670193	670193
PRINTING	667644	254370	3133	410141

All Other Expenses AllOtherExpenses

Field	Value	IRS element (for citing)
Total	1295996	Total
Program Services	607560	ProgramServices
Management And General	442501	ManagementAndGeneral
Fundraising	245935	Fundraising

Total Functional Expenses TotalFunctionalExpenses

Field	Value	IRS element (for citing)
Total	28702803	Total
Program Services	21827940	ProgramServices
Management And General	2220637	ManagementAndGeneral
Fundraising	4654226	Fundraising

Field	Value	IRS element (for citing)
Joint Costs	X	JointCosts

Total Joint Costs TotalJointCosts

Field	Value	IRS element (for citing)
Total	1034553	Total
Program Services	353495	ProgramServices
Management And General	0	ManagementAndGeneral
Fundraising	681058	Fundraising

Cash Non Interest Bearing CashNonInterestBearing

Field	Value	IRS element (for citing)
BOY	6837885	BOY
EOY	6129973	EOY

Savings And Temp Cash Investments SavingsAndTempCashInvestments

Field	Value	IRS element (for citing)
BOY	216839	BOY
EOY	216445	EOY

Pledges And Grants Receivable PledgesAndGrantsReceivable

Field	Value	IRS element (for citing)
BOY	4759033	BOY
EOY	3402758	EOY

Accounts Receivable AccountsReceivable

Field	Value	IRS element (for citing)
BOY	2949128	BOY
EOY	3725105	EOY

Receivables From Officers Etc ReceivablesFromOfficersEtc

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Receivables From Disqual Persons ReceivablesFromDisqualPersons

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Other Notes Loans Receivable Net OtherNotesLoansReceivableNet

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Inventories For Sale Or Use InventoriesForSaleOrUse

Field	Value	IRS element (for citing)
BOY	94865	BOY
EOY	75665	EOY

Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges

Field	Value	IRS element (for citing)
BOY	418292	BOY
EOY	705507	EOY

Field	Value	IRS element (for citing)
Land Buildings Equipment Basis	4890575	LandBuildingsEquipmentBasis
Land Bldg Equipment Accum Deprec	3001968	LandBldgEquipmentAccumDeprec

Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet

Field	Value	IRS element (for citing)
BOY	548947	BOY
EOY	1888607	EOY

Investments Pub Traded Securities InvestmentsPubTradedSecurities

Field	Value	IRS element (for citing)
BOY	20785048	BOY
EOY	23016384	EOY

Investments Other Securities InvestmentsOtherSecurities

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Investments Program Related InvestmentsProgramRelated

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Intangible Assets IntangibleAssets

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Other Assets Total OtherAssetsTotal

Field	Value	IRS element (for citing)
BOY	1394277	BOY
EOY	1227751	EOY

Total Assets TotalAssets

Field	Value	IRS element (for citing)
BOY	38004314	BOY
EOY	40388195	EOY

Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses

Field	Value	IRS element (for citing)
BOY	1894670	BOY
EOY	1732740	EOY

Grants Payable GrantsPayable

Field	Value	IRS element (for citing)
BOY	1394222	BOY
EOY	1713122	EOY

Deferred Revenue DeferredRevenue

Field	Value	IRS element (for citing)
BOY	3003684	BOY
EOY	5428345	EOY

Tax Exempt Bond Liabilities TaxExemptBondLiabilities

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Escrow Account Liability EscrowAccountLiability

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Loans From Officers Directors LoansFromOfficersDirectors

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Mort Notes Pybl Secured Invest Prop MortNotesPyblSecuredInvestProp

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Unsecured Notes Loans Payable UnsecuredNotesLoansPayable

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Other Liabilities OtherLiabilities

Field	Value	IRS element (for citing)
BOY	271653	BOY
EOY	761884	EOY

Total Liabilities TotalLiabilities

Field	Value	IRS element (for citing)
BOY	6564229	BOY
EOY	9636091	EOY

Field	Value	IRS element (for citing)
Follow SFAS117	X	FollowSFAS117

Unrestricted Net Assets UnrestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	20620666	BOY
EOY	21921458	EOY

Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	10486272	BOY
EOY	8493158	EOY

Permanently Restricted Net Assets PermanentlyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	333147	BOY
EOY	337488	EOY

Total Net Assets Fund Balances TotalNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	31440085	BOY
EOY	30752104	EOY

Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	38004314	BOY
EOY	40388195	EOY

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	X	InfoInScheduleOPartXI
Reconcilation Revenue Expenses	-1510495	ReconcilationRevenueExpenses
Reconcilation Other Changes	822514	ReconcilationOtherChanges
Method Of Accounting Accrual	X	MethodOfAccountingAccrual
Accountant Compile Or Review	false	AccountantCompileOrReview
FS Audited	true	FSAudited
Audit Committee	true	AuditCommittee
Financial Statement Separate	X	FinancialStatementSeparate
Federal Grant Audit Required	true	FederalGrantAuditRequired
Federal Grant Audit Performed	true	FederalGrantAuditPerformed

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Publicly Supported Org170b1 Avi	X	PubliclySupportedOrg170b1Avi

Gifts Grants Contrib Received170 GiftsGrantsContribReceived170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	30491706	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	20760601	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	22553697	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	22876129	CurrentTaxYearMinus1Year
Current Tax Year	33247849	CurrentTaxYear
Total	129929982	Total

Total170 Total170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	30491706	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	20760601	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	22553697	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	22876129	CurrentTaxYearMinus1Year
Current Tax Year	33247849	CurrentTaxYear
Total	129929982	Total

Field	Value	IRS element (for citing)
Amounts Subst Contributors Total	5362542	AmountsSubstContributorsTotal
Public Support Total170	124567440	PublicSupportTotal170

Gross Investment Income170 GrossInvestmentIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	842799	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	643473	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	668573	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	951963	CurrentTaxYearMinus1Year
Current Tax Year	897974	CurrentTaxYear
Total	4004782	Total

Other Income170 OtherIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	4177745	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	155966	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	2756152	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	1735330	CurrentTaxYearMinus1Year
Current Tax Year	1624966	CurrentTaxYear
Total	10450159	Total

Field	Value	IRS element (for citing)
Total Support	144384923	TotalSupport
Gross Receipts From Admissions Etc	0	GrossReceiptsFromAdmissionsEtc
Public Support Pertcentage170	0.86274	PublicSupportPertcentage170
Public Support Pertcent Prior Year	0.86316	PublicSupportPertcentPriorYear
Thirty Three Percnt Tests CY170	X	ThirtyThreePercntTestsCY170

Schedule B IRS990ScheduleB

Contributor Info ContributorInfo

Field	Value	IRS element (for citing)
Contributor Number	RESTRICTED	ContributorNumber

Contributor Name Business ContributorNameBusiness

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor Address US ContributorAddressUS

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Aggregate Contributions	RESTRICTED	AggregateContributions

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Total Grassroots Lobbying		TotalGrassrootsLobbying
Total Direct Lobbying		TotalDirectLobbying
Total Lobbying Expenditures		TotalLobbyingExpenditures
Other Exempt Purpose Expenditures		OtherExemptPurposeExpenditures
Total Exempt Purpose Expenditures		TotalExemptPurposeExpenditures
Lobbying Nontaxable		LobbyingNontaxableAmount
Grassroots Nontaxable		GrassrootsNontaxableAmount
Tot Lobbying Grassroot Minus Non Tx		TotLobbyingGrassrootMinusNonTx
Tot Lobby Expend Mns Lobbying Nontx		TotLobbyExpendMnsLobbyingNontx
Volunteers	false	Volunteers
Paid Staff Or Management	true	PaidStaffOrManagement
Media Advertisements	false	MediaAdvertisements
Mailings Members	false	MailingsMembers
Publications Or Broadcast	false	PublicationsOrBroadcast
Grants Other Organizations	false	GrantsOtherOrganizations
Direct Contact Legislators	false	DirectContactLegislators
Rallies Demonstrations	false	RalliesDemonstrations
Other Activities	true	OtherActivities
Other Activities	$193,901	OtherActivitiesAmount
Total Lobbying Expenditures IIB	193901	TotalLobbyingExpendituresIIB
Not Described In501c3	false	NotDescribedIn501c3
Form4720 Filed4912 Tax	false	Form4720Filed4912Tax

Form990 Schedule C Part IV Form990ScheduleCPartIV

Field	Value	IRS element (for citing)
Identifier	Lobbying Expenses	Identifier
Return Reference	Part II-B	ReturnReference
Explanation	The Foundation for AIDS Research developed an Action Agenda to End AIDS that identified critical decisions that need to be made to advance evidence based AIDS policies. We created a variety of issue briefs on topics such as the potential impact of various budget scenarios on global health services, and policy priorities to address the HIV epidemic among gay men in the US. These issue briefs were shared with Capitol Hill staff and members of the Administration. amfAR met regularly with staff to members of Congress and with Administration staff, and we provided input to the Administration on development of the PEPFAR Blueprint for an AIDS Free Generation. amfAR sponsored several briefings on Capitol Hill on AIDS policy and research issues. amfAR uses these briefings as an educational tool.	Explanation

Schedule D IRS990ScheduleD

Art Public Exhibition Amts ArtPublicExhibitionAmts

Field	Value	IRS element (for citing)
Assets In Part X	71978	AssetsInPartX

Field	Value	IRS element (for citing)
Held Works Of Art Amts		HeldWorksOfArtAmts

Collection Used For Other CollectionUsedForOther

Field	Value	IRS element (for citing)
Collection Used For Other Purposes	X	CollectionUsedForOtherPurposes
Description Of Other Purposes	Donated Items, Inventory etc.	DescriptionOfOtherPurposes

Field	Value	IRS element (for citing)
Solicited Assets For Sale	true	SolicitedAssetsForSale

Current Year CurrentYear

Field	Value	IRS element (for citing)
Beginning Of Year Balance	464356	BeginningOfYearBalance
Contributions	4341	Contributions
Investment Earnings Or Losses	52107	InvestmentEarningsOrLosses
End Of Year Balance	520804	EndOfYearBalance

Current Year Minus1 Year CurrentYearMinus1Year

Field	Value	IRS element (for citing)
Beginning Of Year Balance	561083	BeginningOfYearBalance
Contributions	5978	Contributions
Investment Earnings Or Losses	-2705	InvestmentEarningsOrLosses
Other Expenditures	100000	OtherExpenditures
End Of Year Balance	464356	EndOfYearBalance

Current Year Minus2 Years CurrentYearMinus2Years

Field	Value	IRS element (for citing)
Beginning Of Year Balance	516826	BeginningOfYearBalance
Contributions	8258	Contributions
Investment Earnings Or Losses	35999	InvestmentEarningsOrLosses
End Of Year Balance	561083	EndOfYearBalance

Current Year Minus3 Years CurrentYearMinus3Years

Field	Value	IRS element (for citing)
Beginning Of Year Balance	470065	BeginningOfYearBalance
Contributions	9378	Contributions
Investment Earnings Or Losses	37383	InvestmentEarningsOrLosses
End Of Year Balance	516826	EndOfYearBalance

Field	Value	IRS element (for citing)
Permanent Endowment EOY Balance	0.64801	PermanentEndowmentEOYBalance
Term Endowment EOY Balance	0.35199	TermEndowmentEOYBalance
Endowments Held By Unrelated Orgs	false	EndowmentsHeldByUnrelatedOrgs
Endowments Held By Related Orgs	false	EndowmentsHeldByRelatedOrgs
Land		Land
Buildings		Buildings

Leasehold Improvements LeaseholdImprovements

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	781297	OtherCostOrOtherBasis
Depreciation	773409	Depreciation
Book Value	7888	BookValue

Equipment Equipment

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	242387	OtherCostOrOtherBasis
Depreciation	235458	Depreciation
Book Value	6929	BookValue

Other Land Buildings OtherLandBuildings

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	3866891	OtherCostOrOtherBasis
Depreciation	1993101	Depreciation
Book Value	1873790	BookValue

Field	Value	IRS element (for citing)
Total Of Book Value Land Buildings	1888607	TotalOfBookValueLandBuildings
Federal Income Tax Liability	0	FederalIncomeTaxLiability

Other Liabilities OtherLiabilities

Field	Value	IRS element (for citing)
Description	MISCELLANEOUS	Description
Amount	$761,884	Amount

Field	Value	IRS element (for citing)
Total Of Amounts	761884	TotalOfAmounts
Total Revenue	27192308	TotalRevenue
Total Expenses	28702803	TotalExpenses
Excess Or Deficit For Year	-1510495	ExcessOrDeficitForYear
Net Unrealized GL On Investments	836699	NetUnrealizedGLOnInvestments
Other	-$14,185	OtherAmount
Total Adjustments	822514	TotalAdjustments
Excess Or Deficit Per FS	-687981	ExcessOrDeficitPerFS
Tot Revenue Etc Audited Fincl Stmt	28278897	TotRevenueEtcAuditedFinclStmt
Net Unrealized Gains Investments	836699	NetUnrealizedGainsInvestments
Donated Srvc And Use Of Facilities	264075	DonatedSrvcAndUseOfFacilities
Other Revenues	-14185	OtherRevenues
Revenue Not Rptd F990	1086589	RevenueNotRptdF990
Revenue Subtotal	27192308	RevenueSubtotal
Total Revenue Per Form990	27192308	TotalRevenuePerForm990
Tot Expenses Etc Audited Fincl Stmt	28966878	TotExpensesEtcAuditedFinclStmt
Donated Services Use Of Facilities	264075	DonatedServicesUseOfFacilities
Expenses Not Rptd F990	264075	ExpensesNotRptdF990
Expenses Subtotal	28702803	ExpensesSubtotal
Total Expenses Per Form990	28702803	TotalExpensesPerForm990

Form990 Schedule D Part XIV Form990ScheduleDPartXIV (5 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
Endowments	Part V, Line 4	AMFAR's endowment fund is intended to fund the various general research programs the organization sponsors.
FIN 48	Income taxes	Amfar follows guidance that clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a tax return, including issues relating to financial statement recognition and guidance on measurement, classification, interest and penalties, and disclosure. As of September 30, 2012, amfar does not believe that there are any uncertain tax positions within its financial statements. Amfar has processes presently in place to ensure the maintenance of its tax-exempt status; to identify and report unrelated income; to determine its filing and tax obligations in jurisdictions for which it has nexus; and to identify and evaluate other matters that may be considered tax positions. The tax years ended 2009, 2010, and 2012 are still open to audit for both federal and state purposes.
Collections of Art, Histocial Treasures, or other similar assets	Part III, Line 4	AMFAR holds various items of jewelry, photographs and other items of artistic value that have been donated to the organization for sale at special events. The organization has maintained these items in inventory for a few years and is in the process of selling them.
Reconciliation of Revenue	Part XII, Line 2d	Gain on Third Party Trust ($14,185)
Reconciliation of Expenses	Part XIII, LIne 2d	Rounding $4

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	true	GrantRecordsMaintained

Accts Actvs Out US Table AcctsActvsOutUSTable (12 entries)

RegionRegion	Type Of Activities ConductedTypeOfActivitiesConducted	Specific Services ProvidedSpecificServicesProvided	Total ExpendituresTotalExpenditures	Number Of OfficesNumberOfOffices	Number Of EmployeesNumberOfEmployees
Central America and the Caribbean	Grantmaking	N/A	232550
East Asia and the Pacific	Program Services	therapeutics research	1555494	1	18
East Asia and the Pacific	Grantmaking	N/A	3042995	1	18
Europe (Including Iceland and Greenland)	Grantmaking	n/a	838454
Europe (Including Iceland and Greenland)	Fundraising	n/a	3706481
North America	Grantmaking	n/a	220615
North America	Fundraising	n/a	137936
Russia and the Newly Independent States	Grantmaking	n/a	126608
South America	Grantmaking	n/a	163935
South America	Fundraising	n/a	617550
South Asia	Grantmaking	n/a	88306
Sub-Saharan Africa	Grantmaking	n/a	192471

Field	Value	IRS element (for citing)
Subtotal Number Of Offices	2	SubtotalNumberOfOffices
Subtotal Number Of Employees	36	SubtotalNumberOfEmployees
Total Number Of Offices	2	TotalNumberOfOffices
Total Number Of Employees	36	TotalNumberOfEmployees
Subtotal Amount Spent	10923395	SubtotalAmountSpent
Total Amount Spent	10923395	TotalAmountSpent

Grants To Orgs Outside US GrantsToOrgsOutsideUS (158 entries)

RegionRegion	Purpose Of GrantPurposeOfGrant	Amount Of Cash GrantAmountOfCashGrant	Manner Of Cash DisbursementMannerOfCashDisbursement
East Asia/Pacific	BASIC RESEARCH	62499	wire transfe
Europe	BASIC RESEARCH	50000	wire transfe
Europe	BASIC RESEARCH	62496	wire transfe
East Asia/Pacific	BASIC RESEARCH	62501	wire transfe
East Asia/Pacific	TREAT ASIA	21550	wire transfe
East Asia/Pacific	TREAT ASIA	14210	wire transfe
East Asia/Pacific	TREAT ASIA	10650	wire transfe
East Asia/Pacific	TREAT ASIA	14377	wire transfe
East Asia/Pacific	TREAT ASIA	14630	wire transfe
East Asia/Pacific	TREAT ASIA	18640	wire transfe
East Asia/Pacific	TREAT ASIA	15250	wire transfe
East Asia/Pacific	TREAT ASIA	6874	wire transfe
East Asia/Pacific	TREAT ASIA	5374	wire transfe
East Asia/Pacific	TREAT ASIA	6874	wire transfe
East Asia/Pacific	TREAT ASIA	8126	wire transfe
East Asia/Pacific	TREAT ASIA	7125	wire transfe
East Asia/Pacific	TREAT ASIA	7275	wire transfe
Europe	BASIC RESEARCH	180000	wire transfe
Europe	BASIC RESEARCH	53276	wire transfe
North America (excl USA)	BASIC RESEARCH	80000	wire transfe
East Asia/Pacific	TREAT ASIA	5100	wire transfe
East Asia/Pacific	TREAT ASIA	5625	wire transfe
East Asia/Pacific	TREAT ASIA	5775	wire transfe
East Asia/Pacific	TREAT ASIA	6525	wire transfe
East Asia/Pacific	TREAT ASIA	6525	wire transfe
East Asia/Pacific	TREAT ASIA	6600	wire transfe
East Asia/Pacific	TREAT ASIA	6600	wire transfe
East Asia/Pacific	TREAT ASIA	7275	wire transfe
East Asia/Pacific	TREAT ASIA	7500	wire transfe
East Asia/Pacific	TREAT ASIA	19000	wire transfe
East Asia/Pacific	TREAT ASIA	19830	wire transfe
East Asia/Pacific	TREAT ASIA	20000	wire transfe
East Asia/Pacific	TREAT ASIA	15000	wire transfe
South Asia	TREAT ASIA	20000	wire transfe
South Asia	TREAT ASIA	18900	wire transfe
East Asia/Pacific	TREAT ASIA	17533	wire transfe
East Asia/Pacific	TREAT ASIA	18850	wire transfe
East Asia/Pacific	TREAT ASIA	15550	wire transfe
East Asia/Pacific	TREAT ASIA	17700	wire transfe
East Asia/Pacific	TREAT ASIA	12500	wire transfe
East Asia/Pacific	TREAT ASIA	20000	wire transfe
East Asia/Pacific	TREAT ASIA	14325	wire transfe
East Asia/Pacific	TREAT ASIA	15000	wire transfe
East Asia/Pacific	TREAT ASIA	20000	wire transfe
East Asia/Pacific	TREAT ASIA	20000	wire transfe
East Asia/Pacific	TREAT ASIA	20000	wire transfe
East Asia/Pacific	TREAT ASIA	20000	wire transfe
East Asia/Pacific	TREAT ASIA	20000	wire transfe
East Asia/Pacific	TREAT ASIA	15000	wire transfe
South Asia	TREAT ASIA	5625	wire transfe
East Asia/Pacific	TREAT ASIA	5625	wire transfe
East Asia/Pacific	TREAT ASIA	5625	wire transfe
East Asia/Pacific	TREAT ASIA	5625	wire transfe
East Asia/Pacific	TREAT ASIA	5625	wire transfe
East Asia/Pacific	TREAT ASIA	11250	wire transfe
East Asia/Pacific	TREAT ASIA	11250	wire transfe
East Asia/Pacific	TREAT ASIA	11250	wire transfe
East Asia/Pacific	TREAT ASIA	11250	wire transfe
East Asia/Pacific	TREAT ASIA	15000	wire transfe
East Asia/Pacific	TREAT ASIA	5625	wire transfe
East Asia/Pacific	TREAT ASIA	27000	wire transfe
East Asia/Pacific	TREAT ASIA	34985	wire transfe
East Asia/Pacific	TREAT ASIA	35000	wire transfe
East Asia/Pacific	TREAT ASIA	100000	wire transfe
East Asia/Pacific	TREAT ASIA	270471	wire transfe
East Asia/Pacific	TREAT ASIA	20000	wire transfe
East Asia/Pacific	TREAT ASIA	7731	wire transfe
East Asia/Pacific	TREAT ASIA	178698	wire transfe
East Asia/Pacific	TREAT ASIA	174457	wire transfe
East Asia/Pacific	TREAT ASIA	43108	wire transfe
East Asia/Pacific	TREAT ASIA	57547	wire transfe
East Asia/Pacific	TREAT ASIA	20000	wire transfe
East Asia/Pacific	TREAT ASIA	40809	wire transfe
East Asia/Pacific	TREAT ASIA	244844	wire transfe
East Asia/Pacific	TREAT ASIA	21401	wire transfe
East Asia/Pacific	TREAT ASIA	39706	wire transfe
East Asia/Pacific	GMT INITIATIVES	19970	wire transfe
East Asia/Pacific	GMT INITIATIVES	12000	wire transfe
South Asia	GMT INITIATIVES	15567	wire transfe
East Asia/Pacific	GMT INITIATIVES	19958	wire transfe
Europe	BASIC RESEARCH	46872	wire transfe
East Asia/Pacific	TREAT ASIA	58630	wire transfe
East Asia/Pacific	BASIC RESEARCH	110000	wire transfe
Europe	BASIC RESEARCH	110000	wire transfe
East Asia/Pacific	BASIC RESEARCH	31248	wire transfe
Europe	BASIC RESEARCH	164743	wire transfe
East Asia/Pacific	TREAT ASIA	8470	wire transfe
South America	GMT INITIATIVES	20000	wire transfe
South America	GMT INITIATIVES	20000	wire transfe
South America	GMT INITIATIVES	19530	wire transfe
South America	GMT INITIATIVES	19920	wire transfe
Caribbean/Central Americ	GMT INITIATIVES	20000	wire transfe
Caribbean/Central Americ	GMT INITIATIVES	19450	wire transfe
North America (excl USA)	GMT INITIATIVES	15615	wire transfe
Caribbean/Central Americ	GMT INITIATIVES	20000	wire transfe
South America	GMT INITIATIVES	20000	wire transfe
South America	GMT INITIATIVES	20000	wire transfe
South America	GMT INITIATIVES	10985	wire transfe
South America	GMT INITIATIVES	14500	wire transfe
East Asia/Pacific	TREAT ASIA	39149	wire transfe
Europe	BASIC RESEARCH	83200	wire transfe
Sub-Saharan Africa	GMT INITIATIVES	12080	wire transfe
Sub-Saharan Africa	GMT INITIATIVES	12500	wire transfe
Sub-Saharan Africa	GMT INITIATIVES	20100	wire transfe
Sub-Saharan Africa	GMT INITIATIVES	20000	wire transfe
Sub-Saharan Africa	GMT INITIATIVES	10173	wire transfe
Sub-Saharan Africa	GMT INITIATIVES	15000	wire transfe
Sub-Saharan Africa	GMT INITIATIVES	17456	wire transfe
East Asia/Pacific	TREAT ASIA GMT INITIATIVES	6000	wire transfe
East Asia/Pacific	TREAT ASIA GMT INITIATIVES	17000	wire transfe
Caribbean/Central Americ	GMT INITIATIVES	10000	wire transfe
Caribbean/Central Americ	GMT INITIATIVES	19697	wire transfe
Caribbean/Central Americ	GMT INITIATIVES	19908	wire transfe
Caribbean/Central Americ	GMT INITIATIVES	20000	wire transfe
Caribbean/Central Americ	GMT INITIATIVES	20000	wire transfe
Caribbean/Central Americ	GMT INITIATIVES	12495	wire transfe
Caribbean/Central Americ	GMT INITIATIVES	10000	wire transfe
Caribbean/Central Americ	GMT INITIATIVES	10000	wire transfe
Caribbean/Central Americ	GMT INITIATIVES	15000	wire transfe
East Asia/Pacific	BASIC RESEARCH	57288	wire transfe
East Asia/Pacific	TREAT ASIA	5040	wire transfe
Sub-Saharan Africa	GMT INITIATIVES	16200	wire transfe
East Asia/Pacific	TREAT ASIA GMT INITIATIVES	6000	wire transfe
South Asia	TREAT ASIA GMT INITIATIVES	14250	wire transfe
South Asia	GMT INITIATIVES	11960	wire transfe
Sub-Saharan Africa	GMT INITIATIVES	12000	wire transfe
Caribbean/Central Americ	GMT INITIATIVES	12000	wire transfe
Caribbean/Central Americ	GMT INITIATIVES	24000	wire transfe
South America	GMT INITIATIVES	24000	wire transfe
Russia/Newly Independent	GMT INITIATIVES	12000	wire transfe
East Asia/Pacific	TREAT ASIA	6538	wire transfe
East Asia/Pacific	TREAT ASIA	12917	wire transfe
East Asia/Pacific	TREAT ASIA	17089	wire transfe
Europe	BASIC RESEARCH	79867	wire transfe
East Asia/Pacific	TREAT ASIA	8013	wire transfe
East Asia/Pacific	TREAT ASIA	5393	wire transfe
East Asia/Pacific	TREAT ASIA	5251	wire transfe
East Asia/Pacific	TREAT ASIA	5859	wire transfe
East Asia/Pacific	TREAT ASIA	6085	wire transfe
East Asia/Pacific	TREAT ASIA	5876	wire transfe
Russia/Newly Independent	GMT INITIATIVES	19970	wire transfe
Russia/Newly Independent	GMT INITIATIVES	19663	wire transfe
Russia/Newly Independent	GMT INITIATIVES	19975	wire transfe
Europe	GMT INITIATIVES	8000	wire transfe
Russia/Newly Independent	GMT INITIATIVES	20000	wire transfe
Russia/Newly Independent	GMT INITIATIVES	15000	wire transfe
Russia/Newly Independent	GMT INITIATIVES	20000	wire transfe
East Asia/Pacific	GMT INITIATIVES	25000	wire transfe
East Asia/Pacific	TREAT ASIA	100000	wire transfe
East Asia/Pacific	BASIC RESEARCH	26006	wire transfe
Sub-Saharan Africa	PUBLIC POLICY	60555	wire transfe
East Asia/Pacific	TREAT ASIA	10922	wire transfe
East Asia/Pacific	TREAT ASIA	10000	wire transfe
East Asia/Pacific	TREAT ASIA	175000	wire transfe
East Asia/Pacific	TREAT ASIA	175004	wire transfe
East Asia/Pacific	TREAT ASIA	8333	wire transfe
East Asia/Pacific	TREAT ASIA	50000	wire transfe
North America (excl USA)	BASIC RESEARCH	125000	wire transfe

Field	Value	IRS element (for citing)
Total Number Of501c3 Orgs	158	TotalNumberOf501c3Orgs
Transfer To Foreign Corp	false	TransferToForeignCorp
Interest In Foreign Trust	false	InterestInForeignTrust
Own Foreign Corp	false	OwnForeignCorp
Passive Foreign Invest Co	false	PassiveForeignInvestCo
Foreign Partnership	false	ForeignPartnership
Boycott Countries	false	BoycottCountries

Form990 Schedule F Part V Form990ScheduleFPartV (3 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
Foreign Activities	Part I, Line 2	International organizations are recommended for funding based upon the results of community-based peer review and/or program staff assessment of proposal merit and organization capacity to undertake proposed projects that are CHARITABLE in purpose. Pre-award due-diligence for new international grantees includes review of organization documents and registrations to verify that the organization operates for a CHARITABLE purpose and that basic capacity for project oversight and governance has been established. All international grantees are required to report semi-annually on project progress and expenditures; continued reporting is required until such time as grant funds are expended in full. Reports are reviewed by administrative and program staff. Additional oversight is provided as necessary by means of ongoing, informal contact with sites regarding progress and technical issues and site visits where feasible. International research grant recipients submit an interim and a final progress reporting addition to expenditures reports due following the ends of the 2nd, 3rd and final quarters of the performance period.
foreign activities	Part I, Line 3, Column D	The Foundation for AIDS Research conducts many of its grant-making program services (see Part III of Form 990) in U.S. and foreign jurisdictions. In column D, the organization has reported the basic program these grants support; please refer to Part III for more information about these programs/initiatives.
Foreign Activities - Status of Grantees		The Foundation for Aids Research supports many non-U.S. organizations in the fight against AIDS and HIV-related diseases. For purposes of Schedule F, Part II, Line 2 - all 158 charities supported are presumed to be the equivalent of U.S. charities.

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	X	MailSolicitations
Email Solicitations	X	EmailSolicitations
Phone Solicitations	X	PhoneSolicitations
Solicitation Of Non Govt Grants	X	SolicitationOfNonGovtGrants
Solicitation Of Govt Grants	X	SolicitationOfGovtGrants
Special Fundraising Events	X	SpecialFundraisingEvents
Agreement Ref Fundraising	true	AgreementRefFundraising

Fundraiser Activity Information FundraiserActivityInformation (6 entries)

Name Of IndividualNameOfIndividual	ActivityActivity	Fundraiser Control Of FundsFundraiserControlOfFunds	Gross ReceiptsGrossReceipts	Amount Retained By ContractorAmountRetainedByContractor	Net To OrganizationNetToOrganization
aab productions	Fundraising Event/Prod	false	11113567	253625	10859942
john mini consulting inc	direct mail	false	2012934	120750	1892184
public interest communications	tele marketing	false	52634	75489	-22855
sgr consulting	event production	false	448891	36000	412891
telefund	tele marketing	false	69901	55960	13941
sanky communications Inc	Fundraising Counsel	false	389524	102792	286732

Field	Value	IRS element (for citing)
Total Gross Receipts	14087451	TotalGrossReceipts
Total Retained By Contractors	644616	TotalRetainedByContractors
Total Net To Organization	13442835	TotalNetToOrganization
Licensed States	AL	LicensedStates
Licensed States	AK	LicensedStates
Licensed States	AZ	LicensedStates
Licensed States	AR	LicensedStates
Licensed States	CA	LicensedStates
Licensed States	CO	LicensedStates
Licensed States	CT	LicensedStates
Licensed States	DC	LicensedStates
Licensed States	FL	LicensedStates
Licensed States	GA	LicensedStates
Licensed States	HI	LicensedStates
Licensed States	IL	LicensedStates
Licensed States	KS	LicensedStates
Licensed States	KY	LicensedStates
Licensed States	LA	LicensedStates
Licensed States	ME	LicensedStates
Licensed States	MD	LicensedStates
Licensed States	MA	LicensedStates
Licensed States	MI	LicensedStates
Licensed States	MN	LicensedStates
Licensed States	MS	LicensedStates
Licensed States	MO	LicensedStates
Licensed States	NH	LicensedStates
Licensed States	NJ	LicensedStates
Licensed States	NM	LicensedStates
Licensed States	NY	LicensedStates
Licensed States	NC	LicensedStates
Licensed States	ND	LicensedStates
Licensed States	OH	LicensedStates
Licensed States	OK	LicensedStates
Licensed States	OR	LicensedStates
Licensed States	PA	LicensedStates
Licensed States	RI	LicensedStates
Licensed States	SC	LicensedStates
Licensed States	TN	LicensedStates
Licensed States	TX	LicensedStates
Licensed States	UT	LicensedStates
Licensed States	VA	LicensedStates
Licensed States	WA	LicensedStates
Licensed States	WV	LicensedStates
Licensed States	WI	LicensedStates

Events Information EventsInformation

Field	Value	IRS element (for citing)
Name Of Event1	Cannes	NameOfEvent1
Gross Receipts Event1	8115663	GrossReceiptsEvent1
Charitable Contributions Event1	7672663	CharitableContributionsEvent1
Gross Revenue Event1	443000	GrossRevenueEvent1
Cash Prizes Event1	0	CashPrizesEvent1
Non Cash Prizes Event1	0	NonCashPrizesEvent1
Rent Facility Costs Event1	969399	RentFacilityCostsEvent1
Food And Beverage Event1	2090342	FoodAndBeverageEvent1
Entertainment Event1	0	EntertainmentEvent1
Other Direct Expenses Event1	0	OtherDirectExpensesEvent1
Name Of Event2	Dallas	NameOfEvent2
Gross Receipts Event2	5117246	GrossReceiptsEvent2
Charitable Contributions Event2	5016846	CharitableContributionsEvent2
Gross Revenue Event2	100400	GrossRevenueEvent2
Cash Prizes Event2	0	CashPrizesEvent2
Non Cash Prizes Event2	0	NonCashPrizesEvent2
Rent Facility Costs Event2	70611	RentFacilityCostsEvent2
Food And Beverage Event2	2727966	FoodAndBeverageEvent2
Entertainment Event2	0	EntertainmentEvent2
Other Direct Expenses Event2	0	OtherDirectExpensesEvent2
Total Number Of Other Events	14	TotalNumberOfOtherEvents
Gross Receipts Other Events	7111797	GrossReceiptsOtherEvents
Charitable Contrib Other Events	6265767	CharitableContribOtherEvents
Gross Revenue Other Events	846030	GrossRevenueOtherEvents
Cash Prizes Other Events	0	CashPrizesOtherEvents
Non Cash Prizes Other Events	0	NonCashPrizesOtherEvents
Rent Facility Costs Other Events	298109	RentFacilityCostsOtherEvents
Food And Beverage Other Events	2824860	FoodAndBeverageOtherEvents
Entertainment Other Events	0	EntertainmentOtherEvents
Other Direct Expenses Other Events	0	OtherDirectExpensesOtherEvents
Gross Receipts Total	20344706	GrossReceiptsTotal
Charitable Contributions Total	18955276	CharitableContributionsTotal
Gross Revenue Total Events	1389430	GrossRevenueTotalEvents
Cash Prizes Total Events	0	CashPrizesTotalEvents
Non Cash Prizes Total Events	0	NonCashPrizesTotalEvents
Rent Facility Costs Total Events	1338119	RentFacilityCostsTotalEvents
Food And Beverage Total Events	7643168	FoodAndBeverageTotalEvents
Entertainment Total Events	0	EntertainmentTotalEvents
Other Direct Expenses Total Events	0	OtherDirectExpensesTotalEvents
Direct Expense Summary Events	8981287	DirectExpenseSummaryEvents
Net Income Summary	-7591857	NetIncomeSummary

Form990 Schedule G Part IV Form990ScheduleGPartIV

Field	Value	IRS element (for citing)
Identifier	Schedule G, Part I	Identifier
Explanation	The Foundation for AIDS Research actually paid out $491,117 in fundraising expenses for the year ending September 30, 2012. This amount is reported on Part IX, Line 11(e). For purposes of Schedule G, the Foundation is reporting all amounts paid to the consultants listed on Part I, regardless of whether such amounts were pure fundraising expenses or event production costs. On Schedule G, the total amount paid to the organizations listed is $644,617. Of that $644,617, only $491,117 was paid for fundraising services, the remaining $153,500 was paid for event production services. In the interests of clarity, the Foundation would also like to make clear that the compensation reported as having been paid to the professional fundraisers reported on Schedule G is reported on a fiscal year basis. Some of those same fundraisers are reported on the Foundation's Top 5 Highest Paid Independent Contractors list (in Schedule O). In compliance with the instructions to the Form 990, compensation reported for Part VII (and listed in Schedule O) is reported on a calendar year basis. Accordingly, amounts on Part VII and Schedule G will not reconcile.	Explanation

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Records Maintained	true	RecordsMaintained

Recipient Table RecipientTable (50 entries)

Address Line1AddressUS/AddressLine1	CityAddressUS/City	StateAddressUS/State	ZIP CodeAddressUS/ZIPCode	EIN Of RecipientEINOfRecipient	IRC SectionIRCSection	Amount Of Cash GrantAmountOfCashGrant	Purpose Of GrantPurposeOfGrant
Weill Medical College of Cornell
575 Lexington Ave 9th floor	New York	NY	10022	131623978	501(c)(3)	15626	BASIC RESEARCH
University of Texas Southwestern Grants Management
PO Box 841753	Dallas	TX	752841753	175600286	501(c)(3)	15626	BASIC RESEARCH
University of California-Davis
PO Box 989062	West Sacramento	CA	95798	946036494	501(c)(3)	26043	BASIC RESEARCH
California Institute of Technology
1200 E California Bd M/C 201-15	Pasadena	CA	91125	951643307	501(c)(3)	26043	BASIC RESEARCH
University of Minnesota
200 Oak Street SE	Minneapolis	MN	55455	416007513	501(c)(3)	26043	BASIC RESEARCH
Dana Farber Cancer Institute
44 Binney Street BP412	Boston	MA	02115	042263040	501(c)(3)	5208	BASIC RESEARCH
The Board of Regents of the University of Wisconsi
21 North Park Street Suite 6401	Madison	WI	53715	396006492	501(c)(3)	18507	BASIC RESEARCH
Aaron Diamond AIDS Research Center
455 First Avenue 7th Floor	New York	NY	10016	133540234	501(c)(3)	62499	BASIC RESEARCH
VGTI-Florida
11350 SW Village Parkway3rd floor	Port St Lucie	FL	34987	364618350	501(c)(3)	50000	BASIC RESEARCH
The Regents of the University of California Los A
405 Hilgard Ave Box 951432 1125 Mu	Los Angeles	CA	900959000	956006143	501(c)(3)	42857	BASIC RESEARCH
University of Utah Research Accounting
Presidents Circle Rm 406	Salt Lake City	UT	84112	876000525	501(c)(3)	49978	BASIC RESEARCH
The University of Alabama Birmingham
1530 Third Ave South AB990	Birmingham	AL	35294	163605396	501(c)(3)	70000	BASIC RESEARCH
George Mason University
4400 University Dr MS4C6	Fairfax	VA	22030	540836354	501(c)(3)	61540	BASIC RESEARCH
Johns Hopkins University
1830 E Monument Street Ste 8074	Baltimore	MD	21287	520595110	501(c)(3)	56001	BASIC RESEARCH
The Regents University of California
1855 Folsom St MCB 425 Box 0897	San Francisco	CA	941430897	946036493	501(c)(3)	108000	BASIC RESEARCH
University of Pennsylvania
4351 Walnut Street	Philadelphia	PA	191046028	231352685	501(c)(3)	80000	BASIC RESEARCH
Johns Hopkins University Central LockboxDepositor
12529 Collections Center Drive	Chicago	IL	60693	520595110	501(c)(3)	180000	BASIC RESEARCH
Case Western Reserve University School of Medicine
10900 Euclid Ave LC 4960 Wood B	Cleveland	OH	44108	341018992	501(c)(3)	46863	BASIC RESEARCH
Aaron Diamond AIDS Research Center
455 First Ave 7th Floor	New York	NY	100169102	133540234	501(c)(3)	46872	BASIC RESEARCH
New England Primate Research Center Havard Medica
1 Pine Hill Dr RSB6 room 607	Southborough	MA	01772	104210358	501(c)(3)	46872	BASIC RESEARCH
The Regents of the University of California
1855 Folsom Street MCB 425 Box 08	San Francisco	CA	941430897	946036493	501(c)(3)	110000	BASIC RESEARCH
The Regents of the University of California
1855 Folsom Street MCB 425 Box 08	San Francisco	CA	94118	946036493	501(c)(3)	110000	BASIC RESEARCH
The Regents of the University of California
1855 Folsom Street MCB 425 Box 08	San Francisco	CA	94143	946036493	501(c)(3)	110000	BASIC RESEARCH
Johns Hopkins University School of Medicine
200 North Wolfe Street	Baltimore	MD	21205	520595110	501(c)(3)	110000	BASIC RESEARCH
Case Western Reserve University
10900 Euclid Ave BRB 919	Cleveland	OH	44106	341018992	501(c)(3)	110000	BASIC RESEARCH
The Salk Institute for Biological Studies
10010 North Torrey Pines Road	La Jolla	CA	92037	952160097	501(c)(3)	110000	BASIC RESEARCH
Vaccine and Gene Therapy Institute of Florida
11350 SW Village Parkway	Port St Lucie	FL	34987	364631835	501(c)(3)	57289	BASIC RESEARCH
University of Washington
Rosen Building Box 35870	Seattle	WA	98109	916001537	501(c)(3)	57289	BASIC RESEARCH
Vaccine and Gene Therapy Institute of Florida
11350 SW Village Parkway 3rd Floor	Port St Lucie	FL	34987	364631835	501(c)(3)	57289	BASIC RESEARCH
Case School of Medicine
10900 Euclid Ave LC4960	Cleveland	OH	44106	341018992	501(c)(3)	57289	BASIC RESEARCH
The Regents of the University of California
1855 Folsom St MCBH 425 Box 0897	San Francisco	CA	941430897	946036493	501(c)(3)	47410	BASIC RESEARCH
The Regents of the University of California (UCSF)
1001 Portrero Avenue	San Francisco	CA	94110	946036493	501(c)(3)	79952	BASIC RESEARCH
Trustees of the University of Pennsylvania
3451 Walnut Street Suite P221	Philadelphia	PA	19104	231352685	501(c)(3)	96000	BASIC RESEARCH
Johns Hopkins University Central LockboxDepositor
733 North Broadway BRB-871	Baltimore	MD	21205	520595110	501(c)(3)	120000	BASIC RESEARCH
Beth Israel Medical Center
160 Water Street 24th Floor	New York	NY	10038	135564934	501(c)(3)	52354	PUBLIC POLICY
The Fenway Institute
1340 Boylston Street 8th Floor	Boston	MA	02215	042510564	501(c)(3)	25000	GMT INITIATIVES
California Institute of Technology
1200 E California Blvd	Pasadena	CA	91125	951643307	501(c)(3)	83200	BASIC RESEARCH
Case Western Reserve University
10900 Euclid Avenue	Cleveland	OH	44106	341018992	501(c)(3)	83336	BASIC RESEARCH
Massachusetts General Hospital
55 Fruit Street	Boston	MA	02114	042697983	501(c)(3)	83336	BASIC RESEARCH
William J Clinton Foundation
1200 President Clinton Avenue	Little Rock	AR	72201	311580204	501(c)(3)	50000	PREVENTION SCIENCE
Beth Israel Medical Center - Edmond de Rothschild
160 Water Street 24th Floor	New York	NY	10038	135564934	501(c)(3)	67500	PUBLIC POLICY
Tulane University
18703 Three Rivers Road	Covington	LA	70433	720423889	501(c)(3)	46667	BASIC RESEARCH
John Hopkins University
733 N Broadway	Baltimore	MD	212051832	520595110	501(c)(3)	40000	BASIC RESEARCH
John Hopkins University
Department of Medicine 733 North Br	Baltimore	MD	212051832	520595110	501(c)(3)	40000	BASIC RESEARCH
NATIONAL MINORITY AIDS COUNCIL
1931 13th Street NW	Washington	DC	200094423	521578289	501(c)(3)	25000	PUBLIC POLICY
THE BRIGHAM AND WOMEN'S HOSPITAL INC
75 Francis Street	Boston	MA	02115	042312909	501(c)(3)	8763	BASIC RESEARCH
JOHNS HOPKINS UNIVERSITY
733 North Broadway Suite 117	Baltimore	MD	21205	520595110	501(c)(3)	31930	BASIC RESEARCH
END OF AIDS INC
1000 N West Street	Wilmington	DE	19801	454389547	501(c)(3)	125000	PUBLIC POLICY
UNIVERSITY OF PITTSBURGH
123 University Place	Pittsburgh	PA	152132303	250965591	501(c)(3)	125000	GMT INITIATIVES
THE BLACK AIDS INSTITUTE
1833 West Eighth Street 200	Los Angeles	CA	900574920	954742741	501(c)(3)	75000	PUBLIC POLICY

Field	Value	IRS element (for citing)
Total Nbr Of501 C3 And Govt Grants	50	TotalNbrOf501C3AndGovtGrants

Form990 Schedule I Part IV Form990ScheduleIPartIV

Field	Value	IRS element (for citing)
Identifier	Grants and Assistance	Identifier
Return Reference	Part I, Line 2	ReturnReference
Explanation	All U.S. 501(c)(3) grant and award recipients are required to report at least once on activities supported with amfAR funds; all U.S. research grant recipients (which include 501(c)(3) organizations and other nonprofit entities such as state universities) are required to submit an interim and a final progress report in addition to expenditure reports due following the ends of the 2nd, 3rd and final quarters of the performance periods. Reports are reviewed by grant administration and program staff prior to payment and/or closeout.	Explanation

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	X	CompensationCommittee
Independent Consultant	X	IndependentConsultant
Compensation Survey	X	CompensationSurvey
Board Or Committee Approval	X	BoardOrCommitteeApproval
Severance Payment	false	SeverancePayment
Supplemental Nonqual Retire Plan	true	SupplementalNonqualRetirePlan
Equity Based Comp Arrangement	false	EquityBasedCompArrangement
Comp Based On Revenue Of Filing Org	false	CompBasedOnRevenueOfFilingOrg
Comp Based On Revenue Related Orgs	false	CompBasedOnRevenueRelatedOrgs
Comp Based Net Earnings Filing Org	false	CompBasedNetEarningsFilingOrg
Comp Based Net Earnings Relate Orgs	false	CompBasedNetEarningsRelateOrgs
Any Non Fixed Payments	false	AnyNonFixedPayments
Initial Contract Exception	false	InitialContractException

Form990 Schedule J Part II Form990ScheduleJPartII (12 entries)

Base Compensation Filing OrgBaseCompensationFilingOrg	Bonus Filing OrgBonusFilingOrg	Other Compensation Filing OrgOtherCompensationFilingOrg	Deferred Comp Filing OrgDeferredCompFilingOrg	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrg	Total Compensation Filing OrgTotalCompensationFilingOrg
Kevin Frost
361481	0	0	27150	27007	415638
Bradley Jensen
219053	0	0	14977	29757	263787
John F Logan JD PhD
200521	0	0	13907	9361	223789
Rowena Johnston
155658			10965	9361	175984
Edward Donnelly
137426			9419	8636	155481
Gregory L Boroff
223561			15667	9361	248589
Christopher Collins
184540			12230	18182	214952
Annette Sohn
193480			13541	3824	210845
Eric Muscatell
151952			10843	9361	172156
Andrew McInnes
137632			9584	28757	175973
Anthony Ancona
148185			10514	535	159234
AnnMarie Shannahan
187799			13209	9346	210354

Form990 Schedule J Part III Form990ScheduleJPartIII

Field	Value	IRS element (for citing)
Identifier	Compensation	Identifier
Return Reference	Part I, Line 4	ReturnReference
Explanation	Chief Executive Officer, Kevin Frost, participated in a supplemental nonqualified retirement plan; however, he did not receive a distribution in 2011.	Explanation

Schedule M IRS990ScheduleM

Field	Value	IRS element (for citing)
Works Of Art		WorksOfArt
Art Historical Treasures		ArtHistoricalTreasures
Art Fractional Interest		ArtFractionalInterest
Books And Publications		BooksAndPublications
Clothing And Household Goods		ClothingAndHouseholdGoods
Cars And Other Vehicles		CarsAndOtherVehicles
Boats And Planes		BoatsAndPlanes
Intellectual Property		IntellectualProperty

Securities Publicly Traded SecuritiesPubliclyTraded

Field	Value	IRS element (for citing)
Non Cash Checkbox	X	NonCashCheckbox
Noncash Contribs Rptd F990	18387	NoncashContribsRptdF990
Method Of Determining Revenues	sales price	MethodOfDeterminingRevenues

Field	Value	IRS element (for citing)
Securities Closely Held Stock		SecuritiesCloselyHeldStock
Securities Prtnrshp Trust Intrsts		SecuritiesPrtnrshpTrustIntrsts
Securities Miscellaneous		SecuritiesMiscellaneous
Qualified Contrib Hist Struct		QualifiedContribHistStruct
Qualified Contrib Other		QualifiedContribOther
Real Estate Residential		RealEstateResidential
Real Estate Commercial		RealEstateCommercial
Real Estate Other		RealEstateOther
Collectibles		Collectibles
Food Inventory		FoodInventory
Drugs And Medical Supplies		DrugsAndMedicalSupplies
Taxidermy		Taxidermy
Historical Artifacts		HistoricalArtifacts
Scientific Specimens		ScientificSpecimens
Archaeological Artifacts		ArchaeologicalArtifacts

Other Non Cash Contributions Table OtherNonCashContributionsTable

Field	Value	IRS element (for citing)
Non Cash Checkbox	X	NonCashCheckbox
Description	Airline Tickets	Description
Number Of Contributions	16	NumberOfContributions
Noncash Contribs Rptd F990	197793	NoncashContribsRptdF990
Method Of Determining Revenues	Fair Market Value	MethodOfDeterminingRevenues

Field	Value	IRS element (for citing)
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeld
Review Process Unusual NC Gifts	true	ReviewProcessUnusualNCGifts
Third Parties Used	true	ThirdPartiesUsed

Form990 Schedule M Part II Form990ScheduleMPartII

Field	Value	IRS element (for citing)
Identifier	Form 990, Schedule M	Identifier
Explanation	Line 31: To the extent AMFAR receives non-standard contributions, the organization's policy is to liquidate those items into cash for eventual use in support of the organization's mission. Line 32a: When the organization receives contributions of securities, it uses its investment broker to liquidate those holdings to fund amfar's various research program activities.	Explanation

Schedule O IRS990ScheduleO

General Explanation GeneralExplanation (10 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
Program Service Accomplishments (1)	Part III, Line 4a-4d (1)	Line 4a: Research: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health. amfAR fellowships allow talented young investigators to conduct original investigations under the guidance of experienced scientists, helping to ensure the long-term vitality of AIDS research. New Grants and Fellowships Grants and fellowships are awarded through a rigorous process of peer review by a team of independent HIV/AIDS experts drawn largely from the volunteer scientists on amfAR's Scientific Advisory Committee. Guided by its scientific advisors and with the approval of its board of trustees, amfAR pursues a strategic research plan that focuses on the treatment, prevention, and cure of HIV/AIDS. In 2012, amfAR awarded more than $5 million in grants and fellowships to support 34 research projects. Five researchers received Mathilde Krim Fellowships in Basic Biomedical Research, an initiative that provides funding for exceptional young researchers who are new to the field of HIV/AIDS research. The initiative has already achieved spectacular results, including numerous published studies in major scientific journals. The 2012 Krim Fellows-each of whom received between $80,000 and $125,000-are working on new ways to treat HIV/AIDS and its associated conditions, as well as an HIV vaccine. Among the 2012 fellows is Mattias Forsell, Ph.D., of the Karolinska Institute in Stockholm, Sweden, who is aiming to make progress towards the design of a vaccine against HIV infection. Despite a concerted effort to design an AIDS vaccine, several characteristics of the virus, such as its ability to present "decoys" to guide the immune system away from making the most effective immune responses, have made the task impossible so far. Dr. Forsell plans to elucidate the mechanisms whereby the immune cells that make antibodies generate responses to different regions of the virus, and how these cells might ultimately be guided towards making antibodies against the most vulnerable regions of the virus. Cure-Focused Studies Placing the search for a cure for HIV/AIDS at the center of its research efforts, the Foundation launched the amfAR Research Consortium on HIV Eradication (ARCHE) in 2010. In 2012, more than $1.5 million in funding went to seven collaborative teams of researchers working in three areas considered central to HIV eradication: the search for a sterilizing cure to eliminate HIV from the body; the search for a functional cure to suppress the virus without treatment; and the characterization of viral reservoirs, which present an obstacle to a cure. A series of studies by Dr. Sarah Palmer of the Swedish Institute for Infectious Disease Control and Karolinska Institute is building on an intriguing finding made during year two of ARCHE: the discovery of identical clones of latent virus. Dr. Palmer is working with Dr. Frederick Hecht of the University of California at San Francisco to understand how such clones might arise and what they mean for efforts to rid the body of the virus. Dr. Daniel Douek of the National Institutes of Health is also applying his expertise on T cells to help explain the findings. One of the principal strategies being investigated in the search for a cure involves using drugs that can activate HIV out of a latent state, allowing it to be targeted by antiretroviral therapy (ART). Working at Johns Hopkins University, Dr. Robert Siliciano's previous ARCHE research has identified agents-notably, a drug called disulfiram-that might achieve such reactivation. Dr. Siliciano aims to determine whether all of the latent virus can be reactivated. If some virus remains dormant, he will attempt to understand the mechanisms whereby it remains latent despite interactions with drugs that are intended to reverse that latency. Understanding the ability of the virus to remain stubbornly latent will have important ramifications for the design of HIV cure strategies.
Program Service Accomplishments (2)	Part III, Line 4a-4d (2)	LINE 4a, continued: Dr. Timothy Henrich of Harvard is studying two HIV-positive individuals who had been on long-term ART when they developed lymphomas. To treat these cancers, both underwent typical stem-cell transplants from normal donors, who had been selected only for the usual tissue-type match. Dr. Henrich found that not only were these individuals cured of their cancer, but he could find no evidence of HIV. This was true despite the fact that-unlike "The Berlin Patient," who was cured of HIV following transplant with cells from a donor selected for the CCR5 delta32 mutation, and thus resistant to HIV infection-no extraordinary measures were used here. For the moment, these two individuals remain on ART. But with amfAR funding, Dr. Henrich is interrupting their ART in a search for HIV in their blood and other tissues. Current antiretroviral therapy can in many cases reduce levels of HIV to such an extent that sensitive equipment is required to detect it, but the virus can almost always be found. Demonstrating with confidence that a cure has been achieved will require highly sensitive methods of detecting HIV at substantially lower levels than is currently possible. ARCHE grantee Dr. David Margolis of the University of North Carolina is developing just such an ultra-sensitive methodology that could be used in the test tube as well as in subjects participating in clinical trials. Published Research Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In the past year, at least 40 scientific publications resulted from amfAR-funded research. Defining HIV Reservoirs Drs. Sara Palmer and Frederick Hecht (see above) collaborated with colleagues to examine eight HIV-positive individuals and published their findings in the July issue of the Journal of Infectious Diseases. Five of the patients had started ART either during acute infection or early thereafter. Three elected to wait until at least one year following initial infection. All had received ART for at least three years at the time of study. Stem cells were extracted from bone marrow samples using a marker protein known as CD34. The DNA form of HIV was searched for in these cells by an ultra-sensitive assay Dr. Palmer developed years ago, also with amfAR funding. Results with these stem cells were compared to studies of CD4+ T cells obtained from the bone marrow and blood of the same eight subjects. Drs. Palmer and Hecht found that, "a larger pool of HIV-1-infected CD4+ T cells had been established in patients during chronic infection." This is a point critical to the argument that ART should be started as early as possible after identifying an HIV infection. Leading the Charge in Cure Research In the March issue of the journal Cell Stem Cell, three current and former ARCHE grantees, Dr. Keith Jerome of the Fred Hutchinson Cancer Research Center in Seattle and Drs. Steven Deeks and Joseph McCune of the University of California, San Francisco-who met and first discussed the idea for their paper at a stem cell think tank organized by amfAR in September 2011-suggested that one might be able to create an HIV-resistant immune system in an infected person by genetically engineering a person's own stem cells. The authors admit that such "gene modification of stem cells will be an expensive intervention" but suggest that "it may prove to be cost-effective given that decades-long administration of antiretroviral therapy would cost several hundred thousand dollars per person." "Shock and Kill" Strategy Holds Promise in the Search for a Cure Working on the "shock and kill" approach, another ARCHE member, Dr. Siliciano (see above), described his newest findings in the March issue of the Journal of Antimicrobial Chemotherapy. The "shock and kill" approach involves awakening latent virus and then killing it with ARVs, enhanced immune attack, or a combination of these methods. Using a model for latently infected T cells that they developed, Dr. Siliciano and colleagues tested a large number of chemical compounds to see which, if any, might activate growth of HIV without causing harm. They discovered two types of chemicals that not only could awaken HIV but did so without broadly stimulating the cells to produce potentially harmful immune hormones (cytokines). Supporting the possibility of turning such chemicals into useful drugs was the fact that they had characteristics of known drugs that are readily absorbed by the body and taken up by cells. New Targeted RFP amfAR issued a request for proposals (RFP) in September 2012 for biomedical research projects relevant to exploring the mechanisms for HIV persistence and the potential for HIV eradication. Think Tanks, Symposia, and Conferences An amfAR symposium in November 2011 brought together leading scientists, advocates, journalists, and one extraordinary "patient" to discuss the holy grail of AIDS research: a cure. The symposium, titled "Making AIDS History: Closing in on a Cure," featured a conversation between Timothy Brown, "The Berlin Patient," the first adult to be cured of HIV, George Stephanopoulos of ABC News, and Jeffrey Laurence, M.D., senior scientific consultant for programs at amfAR. In June 2012, a think tank organized by amfAR in San Francisco brought together 12 scientists involved in various aspects of HIV cure research, along with two bioethicists, to explore the potential for an HIV cure in infants and children. As a result of the think tank, in September amfAR awarded a grant to Dr. Deborah Persaud of Johns Hopkins Children's Center and Dr. Katherine Luzuriaga of the University of Massachusetts Medical School, enabling them to establish a research collaboratory to explore and document possible pediatric HIV cure cases. The first case of a child cured of HIV was confirmed by researchers in the collaboratory and announced by Dr. Persaud in March 2013. amfAR also played a prominent role in research-focused programming at the XIX International AIDS Conference. Vice President and Director of Research Dr. Rowena Johnston participated in a two-day pre-conference cure symposium-titled "Towards and HIV Cure"-co-chaired by Nobel prize-winning scientist Dr. Franoise Barr-Sinoussi and Dr. Steven Deeks. Dr. Johnston also co-chaired a conference session titled "Gender and Science: Shifting the Paradigm in HIV Research."
Program Service Accomplishments (3)	Part III, Line 4a-4d (3)	Line 4b: TREAT ASIA: amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) involves a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 22 adult and 21 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia HIV Observational Database (TAHOD) TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which now includes anonymous data collected from more than 8,385 patients at 22 clinical sites in 12 countries. The information gathered and analyzed through the database informs the development of more effective research and treatment programs, and helps define treatment standards specific to HIV/AIDS in Asia. In early 2012, the TAHOD network began recruiting participants for a regional study of HIV-tuberculosis co-infection-related to socio-economic determinants of tuberculosis and adverse treatment outcomes, tuberculosis-associated immune reconstitution inflammatory syndrome, and multi-drug resistant tuberculosis. The study protocol and related materials were developed under the leadership of TREAT Asia. TREAT Asia Pediatric Network Representing more than 5,000 HIV-positive children in Asia, TREAT Asia's Pediatric Network includes 21 sites in seven countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database (TApHOD) was modeled on the adult database, and includes data from approximately 4,400 pediatric patients at 16 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam. International AIDS Database TREAT Asia manages the Asia-Pacific section of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. Adolescent Research In 2012, TREAT Asia completed two studies that it hopes will inform and improve adolescent HIV treatment and care in Southeast Asia. This first study examined the incidence of human papillomavirus (HPV) infection-a precursor to cervical and anal cancer-in HIV-positive adolescents. A second study assessed bone mineral density levels in children living with HIV and found preliminary correlations between the use of antiretroviral therapy and bone density loss. In addition, an ongoing study is using an audio-computer-assisted survey instrument (ACASI) to better understand how adolescents experience living with HIV by allowing them to anonymously respond to questions using a computer interface. Reaching Out to MSM Three workshops on the "test and treat" approach for preventing HIV transmission and increasing uptake of HIV testing and treatment services among men who have sex with men (MSM) and transgender women (TG) were held in Thailand in 2012. The workshops were held parallel with a pilot study providing ART to MSM with newly diagnosed HIV, led by the Thai Red Cross AIDS Research Centre. Exploring Links Between HIV and Cancer Among HIV-positive MSM, the risk of anal cancer is twice the level of those who are HIV-negative, but little research has been done on this issue in Asia. With funding from IeDEA, in 2009 TREAT Asia began supporting an innovative research study exploring the links between HIV and anal cancer and looking at cancer biomarkers in an attempt to better identify MSM with pre-cancerous anal lesions. Research on HPV and anal cancer risk among MSM is ongoing in the three original sites in Bangkok, Bali, and Jakarta. Building Research Capacity TREAT Asia has implemented a research education program to help network members strengthen their skills in conducting clinical research and to boost the overall quality of care in the region. TREAT Asia organized eight workshops and training sessions in 2012, including sessions on HIV testing and counseling skills, basic research skills (e.g., manuscript development and scientific writing), and clinical management of HIV. Building Community Treatment Literacy and Promoting Advocacy for Treatment Access Communicating treatment information about a disease as complex as HIV/AIDS can be daunting, but patients' lives depend on it. TREAT Asia works closely with regional organizations to support treatment literacy activities, including the production of "community-friendly" educational brochures on HIV treatment standards in local languages. In 2012, TREAT Asia funded the development of an HIV disclosure book for children and caregivers in collaboration with the South East Asia Research Collaboration with Hawaii (SEARCH) at the Thai Red Cross AIDS Research Centre. The book provides basic information on HIV for children who have recently been told about their HIV diagnosis. The language and illustrations are targeted for younger children in order to help them better understand the implications of having HIV infection. TREAT Asia continued to publish lay-language articles about new research in the fields of prevention, treatment, and basic science. The goal of these articles is to explain HIV/AIDS research advances for people living with HIV/AIDS and their families, communities, and caregivers across Asia. The articles appear in the TREAT Asia Report and on TREAT Asia's website, www.treatasia.org. XIX International AIDS Conference TREAT Asia was well represented at the conference in July 2012 in Washington, D.C. In addition to activities during the main conference, TREAT Asia staff and network investigators participated in pre-conference workshops on HIV pediatric and cure research. Two studies on risk behaviors and treatment outcomes of adolescents from TREAT Asia's pediatric HIV network were presented. 15th Bangkok Symposium on HIV Medicine amfAR continued its support of this annual regional symposium, which was held in January 2012. Dr. Annette Sohn, vice president and director of the TREAT Asia program, spoke about the use of pre-exposure antiretroviral prophylaxis in MSM. 15th International Congress on Infectious Diseases (ICID) TREAT Asia network investigators presented four studies on HIV-infected adolescents at this annual congress, which was held in June 2012 in Bangkok.
Program Service Accomplishments (4)	Part III, Line 4a-4d (4)	Line 4c: EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to stimulate broad awareness of the need for better treatment and prevention methods. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policy makers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. Educational Materials amfAR produces a range of periodicals in both print and electronic formats, including its newsletter Innovations, published twice a year and distributed to more than 40,000 people; the TREAT Asia Report, published and distributed three times a year to more than 4,000 readers in the international health community; and a monthly e-mail newsletter distributed to more than 40,000 people. The Foundation's newly redesigned website features news, interviews, and original articles covering science, policy, the global epidemic, and amfAR programs and activities. amfAR also creates and distributes program reports, press releases, and updates on major HIV/AIDS issues, and conducts public service advertising campaigns that have been instrumental in educating policy makers, healthcare professionals, people living with HIV/AIDS, and the general public. Together to End AIDS amfAR and GBCHealth honored Bill Gates at a benefit event in Washington, D.C., on the eve of the International AIDS Conference, paying tribute to the spirit of global collaboration that has underpinned the world's progress in the fight against AIDS. The event, titled "Together to End AIDS," was attended by Sharon Stone, Anderson Cooper, Jessye Norman, John Corbett, Eve, M?A?C AIDS Fund Chairman John Demsey, The Honorable Nancy Pelosi, UNAIDS Executive Director Michel Sidib, The Honorable Barbara Lee, The Honorable Ed Markey, and Health and Human Services Secretary Kathleen Sebelius, among many others. Gates received amfAR's Award of Courage for his visionary leadership on global health and HIV/AIDS. The evening kicked off the first International AIDS Conference to be held in the U.S. in more than two decades. Social Media amfAR vigorously expanded its presence in the social media arena, reaching large numbers of a people and a generally younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly added content to its Facebook page, mounted a campaign to increase Facebook followers, and live tweeted from fundraising and program events. amfAR passed 40,000 likes on Facebook in 2012 and now has more than 15,000 Twitter followers. Media Outreach amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS press coverage. Articles and reports involving amfAR-many of which included interviews with amfAR spokespeople-were carried in numerous media outlets, including The New York Times, The Wall Street Journal, The Washington Post, the Associated Press, Reuters, Bloomberg News, and The Huffington Post. amfAR's leadership role in AIDS research was highlighted in late July, during and around the International AIDS Conference in Washington, D.C., when major outlets-including The Wall Street Journal, the Associated Press, Bloomberg, and Reuters-sought commentary from amfAR's leadership. amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing steadfast support of Global Fundraising Chairman Sharon Stone. In 2012, celebrity supporters included amfAR ambassadors Cheyenne Jackson, Janet Jackson, Milla Jovovich, Liza Minnelli, and Michelle Yeoh, as well as Sarah Jessica Parker, Heidi Klum, Alan Cumming, John Benjamin Hickey, Janelle Mone, Jennifer Hudson, Elizabeth Hurley, Debbie Harry, Diane Kruger, Kylie Minogue, fun., Jessie J, Theophilus London, Chris Tucker, Adrien Brody, Dita Von Teese, Stanley Tucci, Chelsea Handler, and Katy Perry, among many others.
Program Service Accomplishments (5)	Part III, Line 4a-4d (5)	THE GMT INITIATIVE (formerly MSM Initiative): Since 2007, amfAR has been serving the HIV-related needs of gay men, other men who have sex with men (MSM), and transgender individuals (collectively, GMT) throughout the developing world through its MSM Initiative. The program was recently renamed The GMT Initiative to better reflect the diversity of the people it serves. Through small, targeted grants to grassroots groups, amfAR helps expand access to HIV education and prevention services; supports advocacy aimed at increasing funding for prevention and treatment services; and works to end the stigma, discrimination, and violence that threaten the lives of GMT and fuel the spread of HIV/AIDS. Community Awards In 2012, amfAR awarded more than $650,000 to 39 groups in Africa, Asia and the Pacific, the Caribbean, Eastern Europe and Central Asia, and Latin America for a wide range of projects addressing HIV prevention, outreach, education, advocacy, testing, research, and capacity building. Sample funded projects include: Africa Espoir Vie Togo (EVT) (Lom, Togo) EVT is helping to create the first ever safe space for LGBT people and other MSM in Togo. Ahoefa-The House of Peace-provides access to psychosocial support, HIV testing and counseling, prevention discussion groups, condoms, and lubricant. The group is also providing financial support for scholarships for deserving students, micro-credit programs, and vocational skills training. EVT is engaging policy makers, media representatives, religious leaders, and health care workers in discussions about stigma and homophobia and their effects on HIV vulnerability among MSM. Asia-Pacific The Human Rights Education Institute of Burma (HREIB) (Chiang Mai/Ranong, Thailand) This direct service project is supporting peer educators who teach sexual health-related knowledge and risk-reduction skills, increasing access to healthcare and vocational training, and promoting basic human rights among Burmese migrant MSM and transgender persons living in Ranong, Thailand. Caribbean Grupo Este Amor (La Romana, Dominican Republic) This transgender-specific project is helping transgender women achieve economic independence by providing HIV prevention education and small business skills. Grupo Este Amor is training transgender stylists who double as health agents to their clients, providing HIV prevention information and condoms, and encouraging HIV testing and referrals. Eastern Europe and Central Asia Penitentiary Initiative (Nikolaev, Ukraine) Based on multiple previous amfAR awards, the group advocates on behalf of, and provides services for, "outcast" GMT in prison settings, including psychological support groups and individual counseling. The organization, which received its fourth grant from amfAR, is also piloting new strategies (such as rapid HIV testing) in three prisons, as well as continuing to hold training seminars with Ministry of Justice officials on both medical and non-medical aspects of living with HIV. Latin America Fundacin Llanto, Valor y Esfuerzo (LLAVES) (San Pedro Sula, Honduras) LLAVES is training key transgender leaders to become educated in policy, law, and human rights in order to amend the Honduran Special Law on HIV to include protection for all citizens regardless of sexual orientation and gender identity. Additionally, LLAVES is working with local media to increase awareness of issues such as HIV, human rights, and sexual diversity. "In Action" Awards The GMT Initiative also made five awards as part of its Advocacy in Action program, which supports GMT-led community-based organizations that wish to influence the policies of governments and external donors. Six additional awards were made under its Evidence in Action program, which documents and evaluates the impact of community-based programs with the ultimate goal of implementing the most workable strategies for stopping the spread of HIV/AIDS. Evidence in Action was developed with support from ViiV Healthcare's Positive Action Program and the Elton John AIDS Foundation. Awards for these two programs in 2012 totaled more than $180,000. Publications As part of its efforts to raise awareness among governments, donors, and international nongovernmental organizations of the spread of HIV among GMT and to advocate effective strategies for addressing it, amfAR publishes reports on HIV and GMT. In November 2011, amfAR published a Fundraising Toolkit for GMT-led advocacy in low- and middle-income countries, offering general tips on fundraising and information about who is funding GMT groups. The toolkit is available in English, Russian, and Spanish. And with the Johns Hopkins Bloomberg School of Public Health, amfAR published Achieving an AIDS-Free Generation for Gay Men and Other MSM, a new report providing the most comprehensive analysis to date of HIV-related funding and programming for this population. XIX International AIDS Conference Led by Director Kent Klindera, the GMT Initiative was well represented at the XIX International AIDS Conference, with several community partners presenting data from amfAR-supported projects. Highlights included a presentation on sustainable funding during a Global Forum on MSM and HIV pre-conference meeting, and a skills-building session on community engagement in GMT-related research.
Program Service Accomplishments (6)	Part III, Line 4a-4d (6)	public policy: Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. The Foundation is engaged in efforts to secure necessary increases in funding for HIV/AIDS research; implement the new National HIV/AIDS Strategy; expand access to care and treatment; and protect the civil rights of all people affected by HIV/AIDS. Capitol Hill Briefings PEPFAR and Combination Prevention for an AIDS-Free Generation February 1, 2012 amfAR co-hosted a briefing-with the IDSA Center for Global Health Policy and the President's Emergency Plan for AIDS Relief (PEPFAR)-to discuss combination prevention approaches to HIV. Speakers were U.S. Global AIDS Coordinator Dr. Eric Goosby, Dr. Diane Havlir of the University of California, San Francisco, Dr. Chris Beyrer of the Johns Hopkins Center for Public Health and Human Rights, Dr. RJ Simonds of the Elizabeth Glaser Pediatric AIDS Foundation, and Dr. Renee Ridzon of the Bill & Melinda Gates Foundation. Beginning to End the AIDS Epidemic: What's the Research Agenda? May 23, 2012 Panelists reviewed and discussed current and upcoming areas of HIV-related research, including microbicides, pre-exposure prophylaxis (PrEP), treatment as prevention, vaccines, and the search for a cure. Speakers included Dr. Carl Dieffenbach of the National Institute of Allergy and Infectious Diseases, Dzon Dixon Diallo of SisterLove, Inc. and Morehouse School of Medicine; and Dr. Jared Baeten of the University of Washington. A Cure for HIV/AIDS: Recent Breakthroughs and New Research Frontiers June 20, 2012 In addition to two panels of top HIV/AIDS researchers and advocates, the briefing included an interview by Judy Woodruff, co-anchor and senior correspondent of PBS News Hour, with Timothy Brown, "The Berlin Patient," the first person known to be cured of HIV. During the first panel, amfAR grantee Dr. Robert Siliciano of Johns Hopkins University School of Medicine, described his work studying ways to force latent HIV that is lying dormant in cells to become active so that it can be targeted by antiretroviral therapy. The second panel featured amfAR Trustee Regan Hofmann, former editor of POZ magazine, who urged policymakers to seize on recent scientific advances now. Harm Reduction As one of the earliest supporters of comprehensive harm reduction programs for injection drug users (IDUs), including syringe exchange, amfAR has played a leading role in advocating the implementation of these lifesaving HIV prevention programs. Immediately prior to the opening of the 2012 International AIDS Conference, amfAR and the International AIDS Society - with financial and planning support from the Open Society Foundations - convened a day-long meeting to review available evidence on effective strategies to combat HIV among people who use drugs. The meeting attracted approximately 200 participants from 30 countries, including researchers, clinicians, government officials, community-based organizations, AIDS advocates, people who use drugs, and people living with HIV. amfAR funds the only annual national survey of U.S. SEPs, which is traditionally published in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report (MMWR). Under contract with the New York State Department of Health's AIDS Institute, amfAR continued to administer the distribution of harm reduction supplies to the 21 authorized SEPs statewide, which have served more than 160,000 registered participants. Shaping the Domestic Response to HIV/AIDS amfAR has long advocated the implementation of a comprehensive national HIV/AIDS strategy to address the epidemic in the U.S., where more than one million people are living with the virus. In March, amfAR spearheaded a successful consultation on the research agenda for use of modeling in addressing the domestic epidemic. More than 30 planners, AIDS directors, advocates, and modelers attended. Public policy staff members met with the new Office of National AIDS Policy (ONAP) Director Grant Colfax to discuss priorities, and set up and attended meetings on domestic appropriations with key Congressional staff. Global Health At the International AIDS Conference, amfAR released an "Action Agenda to End AIDS," developed with AVAC to identify five major short-term priorities for global AIDS programs together with realistic, annual targets through 2015. The report was the focus of a satellite session at the conference titled "Getting Real About Getting to the End of AIDS." A panel discussion moderated by renowned journalist Charlayne Hunter-Gault included Anthony Fauci, M.D., of the National Institute of Allergy and Infectious Diseases; Mike Cohen, M.D., of the University of North Carolina; Helen Rees, M.D., of the Wits Reproductive Health and HIV Institute in South Africa; Chris Collins, amfAR vice president and director of public policy; Mitchell Warren, executive director of AVAC; and other leading AIDS experts. GMT GMT-gay men, other men who have sex with men, and transgender individuals-remain one of the hardest hit and most underserved populations in the global HIV/AIDS epidemic. amfAR's policy office works closely with the Foundation's GMT Initiative (formerly MSM Initiative) to advocate expanded access to HIV prevention and treatment services for GMT worldwide, and to fight the stigma and discrimination that make GMT more vulnerable to HIV infection and inhibit equal access to care. In January, amfAR released a new report-titled "Achieving an AIDS-Free Generation for Gay Men and Other MSM"-on global funding and policy related to tackling the HIV epidemic among gay men and other MSM. The report provides the most comprehensive analysis to date of HIV-related funding and programming for this population. Focusing on eight countries, it finds that national governments have failed to adequately address the epidemic among MSM, particularly in countries that criminalize same-sex sexual behavior. At the International AIDS Conference, amfAR played a key role in a symposium session titled "Men Who Have Sex with Men and HIV"-hosted by The Lancet, whose July 28, 2012, issue featured a series on the same theme, including two articles co-authored by amfAR Vice President and Director of Public Policy Chris Collins. Collins presented one of the articles, "A call to action for comprehensive HIV services for men who have sex with men." An issue brief released by amfAR and Trust for America's Health (TFAH) in September-Ending the HIV Epidemic Among Gay Men in the United States-argues that more frequent HIV testing and linkage to appropriate care, in combination with traditional prevention measures such as consistent use of condoms and safer sex practices, are needed to bring down HIV incidence among gay men. It called for systematic changes to reduce barriers to HIV testing and treatment for gay men, including expanded provider education and training, insurance coverage, and utilization of new testing technologies. The report also urged LGBT community organizations to rededicate themselves to fighting AIDS in America. Pre-Exposure Prophylaxis (PrEP) As part of a coalition of AIDS advocacy organizations, amfAR called on the U.S. Food and Drug Administration (FDA) early in 2012 to approve the antiretroviral drug Truvada as pre-exposure prophylaxis (PrEP), and, in testimony before the advisory panel, emphasized the need for demonstration projects to determine how PrEP can be used for optimal public health impact. In July, amfAR applauded the FDA's decision to approve use of Truvada as an option for HIV prevention. The decision followed a May 10 recommendation by an advisory panel to the agency, which said that Truvada, currently approved for HIV treatment, is also a safe and effective means to prevent infection in sexually active adults. The drug, manufactured by Gilead Sciences Inc., was studied in several major trials that demonstrated the once-daily pill, when taken consistently, significantly reduces the chances of acquiring HIV. amfAR continues to advise the U.S. Government on how to incorporate Truvada into global prevention strategies and goals.
Policies	Form 990, Part VI, Section B	Line 11 - The Form 990 was prepared by a nationally renowned accounting firm in conjunction with the organization's financial department. A copy of the draft Form 990 was circulated to the full Board of Trustees for discussion and comment. Each Board Member was provided ample opportunity to comment on the information contained in the 990 prior to its filing with the Internal Revenue Service. Line 12 - Each officer, director, trustee and key employee of amFar ("foundation") is required to annually disclose any conflicts of interest that arise by virtue of employment, board service, or position with the foundation. The foundation monitors compliance with its conflict of interest policy through an annual questionnaire/disclosure statement that is distributed to these individuals. Potential conflicts are investigated immediately. LINE 15 - AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS.
Disclosure	Form 990, Part VI, Section C	LIne 19 - amfar makes its Form 990 available to the public by retaining a copy at its place of business and on its website, www.amfar.org. The Form 990 is likewise published on the internet at www.guidestar.org. The Foundation's financial statements are made available in its annual report and on its website. The Foundation's governing documents and conflict of interest policy are not ordinarily made available to the public, but, if requested, will be provided at management's discretion.
Functional Expenses	Part IX, Lines 1 & 3	The Foundation for AIDS Research reports its grants net of grant returns or recoveries. Periodically, grants remitted to charitable organizations are returned to AMFAR for a variety of reason. On Schedules F & I, grants are reported irrespective of whether they were ultimately returned to AMFAR since categorizing the "returned" amounts would be time consuming. Therefore, amounts reported on Part IX, Line 1 may not necessarily tie to total grants on Schedule I; amounts reported on Part IX, Line 3 may not necessarily tie to total grants on Schedule F.
Other Changes in Net Assets	FORM 990, SECTION XI, LINE 5	unrealized gain..............$836,699 gain on third party trust.... (14,185) ---------- ($822,514) ==========